

REMARKS

Applicants have received and reviewed the Office Action dated January 26, 2010. Applicants request entry of this Amendment and reconsideration of the rejection of the claims.

By way of response, Applicants have cancelled claim 69 without prejudice. Applicants reserve the right to pursue the subject matter of this claim in a continuation application

Claims 29, 32, and 68 have been amended. The amendments are supported throughout the specification including at page 26, lines 13-26, and page 18 lines 20-24.

Interview Summary

Applicants thank the Examiner for the interview on June 8, 2010. We discussed submitting a substitute sequence listing, and a substitute specification including sequence identifiers. We discussed proposed amendments to overcome the 102 rejection.

35 USC 112, first paragraph

The Examiner rejected claims 29, 30, 32, and 67 under 35 USC 112, first paragraph. The examiner contends that the SEQ ID No:8 and the sequences set forth at 20+ are new matter. While not acquiescing to the rejection and solely to expedite prosecution, applicants hereby submit a sequence listing with sequence of SEQ ID NOs 21-24 deleted. Applicants submit that the specification provides support for the polypeptide having the sequence of SEQ ID NO:8 in the least at page 20, lines 11, 22, and 34. Applicants submit that the sequence for SEQ ID NO:20 is supported in the least at page 54, Table 8. Applicants also hereby submit a substitute specification inserting SEQ ID NOs for the sequences at pages 20-25. Applicants request withdrawal of this rejection.

35 U.S.C. § 112, second paragraph

Claims 29, 30, 32 and 67-69 were rejected under 35 U.S.C. 112, second paragraph, as being indefinite. The examiner contends that the term "substantially" renders the claim indefinite. Claim 69 is cancelled rendering the rejection of this claim moot. While not acquiescing to the rejection and solely to expedite prosecution, the claims no longer include that term. Applicants request withdrawal of this rejection.

35 U.S.C. § 102(b)

Claims 29, 30 and 68 were rejected under 35 U.S.C. § 102(b) as anticipated by Vaughan-Thomas et al., 2001. Applicants traverse this rejection.

A claim is anticipated only if each and every element as set forth in the claim is found, either expressly or inherently described, in a single prior art reference. *Verdegaal Bros. v. Union Oil Co. of California*, 814 F.2d 628, 631 (Fed. Cir. 1987); *See also*, MPEP §2131.

Claim 29 is now directed to a composition for treating or preventing arthritis or other degenerative disease, said composition comprising one or more polypeptides having at least 80 % amino acid identity to SEQ ID NO: 14 and having an amino acid length of less than 250 amino acids in combination with a physiological acceptable carrier, wherein the polypeptide comprises one or more polypeptide fragments selected from:

- (a) KSVSFSYKG (SEQ ID NO: 2);
- (b) KIMIGVERS (SEQ ID NO: 3);
- (c) RIESLPIKPRG (SEQ ID NO: 5);
- (d) KHWSIWQIQDSSGKE (SEQ ID NO: 6);
- (e) RIGQDDLPGFDLISQFQIDKA (SEQ ID NO: 7);
- (f) RHLYPNGLPEEYSFLTTFRM (SEQ ID NO: 8);
- (g) KGLDGSLQTAAFSNLPSLFDSQWHKI (SEQ ID NO: 9);
- (h) RSSATLFDVCNRI [SEQ ID NO: 11]; and
- (i) KLGNNVDFRI (SEQ ID NO: 4).

Applicants submit that the Vaughan –Thomas reference does not disclose all of the elements of the claim 29. In the least, the Vaughan Thomas reference does not disclose a composition comprising one or more polypeptides having at least 80% sequence identity to SEQ ID NO:14. Vaughan Thomas is a database entry that discloses a nucleic acid and predicted amino acid sequence. There is no teaching or suggestion in this reference of isolating the polypeptides having the claimed characteristics and/or formulating a composition. Applicants request withdrawal of the rejection on this basis.

Claim 68 is directed to a composition for treating or preventing arthritis or other degenerative disease, said composition comprising one or more polypeptides having at least 65% amino acid identity to SEQ ID NO:14 and having an amino acid length of less than 250 amino acids in an amount effective to decrease inflammation, in combination with a physiological

acceptable carrier, wherein the polypeptide has a molecular weight of less than 30,000 Da and greater than or equal to 10,000 Da and wherein said polypeptide induces tolerance to cartilage.

Applicants submit that the Vaughan-Thomas reference does not disclose all of the elements of the claim 68. In the least, the Vaughan Thomas reference does not disclose a composition comprising one or more polypeptides having at least 65% sequence identity to SEQ ID NO:14 in an amount effective to decrease inflammation. Vaughan Thomas is a database entry that discloses a nucleic acid and predicted amino acid sequence. There is no teaching or suggestion in this reference of isolating the polypeptides having the claimed characteristics and/or formulating a composition with an effective amount to decrease inflammation. Further, Vaughan Thomas, does not disclose that the polypeptide induce tolerance to cartilage. Since the Vaughan Thomas reference does not at all disclose any of the properties of the claimed polypeptides it cannot anticipate the claim. Applicants request withdrawal of the rejection on this basis.

Summary

In view of the above amendments and remarks, Applicant respectfully requests a Notice of Allowance. If the Examiner believes a telephone conference would advance the prosecution of this application, the Examiner is invited to telephone the undersigned at the below-listed telephone number.


Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Date:

July 21, 2010


Katherine M. Kowalchuk
Reg. No. 36,848

KMK:kf

CONNECTIVE TISSUE DERIVED POLYPEPTIDES

This application is the National Stage Application of International Application No. PCT/DK2004/000788, filed on June 17, 2004, which claims priority to Application No. 2003 90 3037, filed on June 17, 2003 in Denmark.

TECHNICAL FIELD

The present invention relates to methods for treating and preventing arthritis and other degenerative diseases and to inducing tolerance in an individual to an antigenic component of cartilage, the present invention also relates to novel methods for preparing and recovering connective tissue derived polypeptides, their uses in methods of treatment, and protection of connective tissues in arthritis and other degenerative diseases.

BACKGROUND OF THE INVENTION***1. General***

As used in the specification and claims, the singular form "a," "an" and "the" include plural references unless the context clearly dictates otherwise. For example, the term "a fungal pathogen" includes a plurality of fungal pathogens, including mixtures thereof.

As used herein the term "derived from" shall be taken to indicate that a specified integer are obtained from a particular source albeit not necessarily directly from that source.

A "composition" is intended to mean a combination of active agent and another compound or composition, inert (for example, a detectable agent or label) or active, such as an adjuvant.

Unless the context requires otherwise or specifically stated to the contrary, integers, steps, or elements of the invention recited herein as singular integers, steps or elements clearly encompass both singular and plural forms of the recited integers, steps or elements.

The embodiments of the invention described herein with respect to any single embodiment shall be taken to apply mutatis mutandis to any other embodiment of the invention described herein.

Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated step or element or integer or group of steps or elements

or integers but not the exclusion of any other step or element or integer or group of elements or integers.

Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations or any two or more of said steps or features.

The present invention is not to be limited in scope by the specific examples described herein. Functionally equivalent products, compositions and methods are clearly within the scope of the invention, as described herein.

The present invention is performed without undue experimentation using, unless otherwise indicated, conventional techniques of molecular biology, microbiology, virology, recombinant DNA technology, peptide synthesis in solution, solid phase peptide synthesis, and immunology. Such procedures are described, for example, in the following texts that are incorporated herein by reference:

1. Sambrook, Fritsch & Maniatis, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratories, New York, Second Edition (1989), whole of Vols I, II, and III;
2. *DNA Cloning: A Practical Approach*, Vols. I and II (D. N. Glover, ed., 1985), IRL Press, Oxford, whole of text;
3. *Oligonucleotide Synthesis: A Practical Approach* (M. J. Gait, ed., 1984) IRL Press, Oxford, whole of text, and particularly the papers therein by Gait, pp 1-22; Atkinson et al., pp35-81; Sproat et al., pp 83-115; and Wu et al., pp 135151;
4. *Nucleic Acid Hybridization: A Practical Approach* (B. D. Hames & S. J. Higgins, eds., 1985) IRL Press, Oxford, whole of text;
5. Perbal, B., *A Practical Guide to Molecular Cloning* (1984);
6. Wiinsch, E., ed. (1974) *Synthese von Peptiden in Houben-Weyls Methoden der Organischen Chemie* (Miiler, E., ed.), vol. 15, 4th edn., Parts 1 and 2, 30 Thieme, Stuttgart.
7. *Handbook of Experimental Immunology*, Vols. I-IV (D. M. Weir and C. C. Blackwell, eds., 1986, Blackwell Scientific Publications)

Bibliographic details of the publications referred to in this specification are collected at the end of the description

2. Background art

Diseases of the musculoskeletal system such as rheumatoid arthritis (RA), osteoarthritis (OA), disc degeneration (DD), and osteoporosis (OP) are a major cause of morbidity throughout the world. These diseases have a substantial influence on health and quality of life and inflict an enormous cost on health systems.

The aetiology of OA is considered to be multi-factorial with ageing, mechanical, hormonal and genetic factors all contributing to varying degrees. OA emerges as a clinical syndrome when these etiological determinants result in sufficient joint tissue damage to cause synovial inflammation and the appearance of the symptoms of pain and impairment of function.

RA is thought to arise as a consequence of extrinsic and/or intrinsic triggering of an autoimmune response in genetically susceptible individuals. The aggressive inflammation initiated in the joints of RA patients by the activation of their immune system is manifest by the release of pro-inflammatory cytokines, proteinases and free radicals. All of these mediators have the ability to promote the destruction of cartilage, bone and other intra-articular joint tissues leading to further impairment of joint function and progression of the disease. While both OA and RA show common pathological features of cartilage destruction and synovial inflammation, the origins and temporal history of these events are clearly distinct. Nevertheless, destruction of joint cartilage is common to both OA and RA and there is now strong evidence that the breakdown and release of the matrix components from cartilage play a significant role in the chronicity of these diseases.

Cartilage may be considered as an anisotropic biomaterial composed essentially of a three-dimensional fibrous network of type II collagen fibrils copolymerised with types IX and XI collagens embedded in a proteoglycan (PG) rich hydrated extracellular matrix. Type II collagen accounts for over 90% of the total collagen of adult cartilage while the type IX content is only 1-2%.

Type IX collagen is a heteropolymer consisting of three genetically distinct alpha chains, $\alpha 1$ (IX), $\alpha 2$ (IX) and $\alpha 3$ (IX) whose molecular structure and amino acid sequences have been described (Pihlajamäki T, et al. Characterisation of recombinant human type IX collagen, association of α chains into homotrimeric and heterotrimeric molecules. J Biol Chem, **274**: 22464-22468, 1999)(US Patent 6,127,523, October 3, 2000). The type IX α -chains contain 3 triple-helical domains, COL1, COL2 and COL3 and four non-collagenous domains, NC1, NC2, NC3 and NC4. The NC1 and NC3 regions contain cysteine residues that can form intramolecular disulfide linkages

between the α -chains. Only the $\alpha 1(\text{IX})$ chain contains a NC4 domain (see Figure 1) and the sequence from chick sternia has been shown to consist of 243 amino acid residues with a calculated molecular mass of 27,139Da and overall positive charge (Vasios G, Nishimura I, Konomi H, van der Rest M, Cartilage Type IX collagen-proteoglycan contains a large amino-terminal globular domain encoded by multiple exons. J Biol Chem 263: 2324-2329,1988).

The type IX collagen heteropolymer is linear except that the NC3 domain acts like a hinge allowing the NC4 region of the $\alpha 1$ chain to project away from the other chains. Interestingly, a single chondroitin sulfate chain is attached to the NC3 domain.

Although only a minor component of cartilage, type IX collagen provides an important role in maintaining the type II collagen fibrous network assembly which is essential for the optimum physical function of this weight-bearing tissue. Type IX collagen resides on the surface of the type II collagen fibrils to which it is covalently linked via, at least 2 trivalent pyridinoline cross-links, particularly at sites where the type II fibril network intersects. By cross-linking the type II collagen fibrils type IX collagen would appear to constrain the expansion caused by the imbibition of water molecules attracted into the tissue by the trapped negatively charged proteoglycan (PG) aggregates (referred to herein as aggrecans). In addition the positively charge centres on the globular NC4 domain also provides a potential binding site for the polyanionic aggrecans.

The aggrecans of cartilage are macro-molecular aggregates of PG subunits which are non-covalently attached along the length of a hyaluronic acid chain. Each aggrecan may contain 20-50 PG subunits and their interaction with the HA backbone is stabilised by ternary interactions with link protein. The PG subunits consist of a protein core to which up to 100 GAG chains are covalently linked. The major GAG substituents of the PGs are the chondroitin sulfates (ChS) and keratan sulfate.

In addition to the collagens and proteoglycans, cartilage also contains a large number of non-collagenous proteins, the most abundant being cartilage oligomeric protein (COMP), cartilage matrix protein (CMP), and thrombospondin. COMP is considered to be a key structural component of the cartilage matrix since it interacts with type IX collagen and plays a role in the development and assembly of type II collagen fibrils (Holden P, et al. Cartilage oligomeric matrix protein interacts with type IX collagen and disruptions to these interactions identify a pathogenic mechanism in a bone dysplasia family. J Biol Chem, 276: 6046-6055, 2001). In the early stages of arthritis when cartilage breakdown is increased, PGs, type IX collagen and COMP fragments are some of the first matrix components to be released into synovial fluid by

the action of endogenous proteinases. These products of cartilage breakdown have been shown to be antigenic and can induce an inflammatory response within arthritic joints thereby contributing to the rate of disease progression.

In arthritic diseases, the excessive breakdown of cartilage and bone and the concomitant elicitation of an inflammatory reaction provoked by the release of autoantigens are responsible for their chronicity. However, there is accumulating evidence to indicate that these matrix molecules could also be responsible for the initiation of joint diseases by acting as autoantigens. Indeed, systemic administration of type II collagen or other matrix components together with adjuvants to laboratory animals have been used to produce animal models of arthritic disease (Creamer MA, Rosloniec EF, Kang AH. The cartilage collagens: a review of their structure, organization and role in the pathogenesis of experimental arthritis in animals and human rheumatic disease, *J Mol Med*, **76**: 275-288, 1998).

In the case of cartilage collagens, this knowledge has led to the development of means of treating rheumatic diseases by using the concept of oral tolerisation (Weiner, HL, Komagata Y. Oral tolerance and the treatment of Rheumatoid Arthritis. *Seminars Immunopath*, **20**: 289-308, 1998). Thus it has been shown that suppression of type II collagen-induced arthritis in animal models can be achieved by oral administration of low doses of type II collagen. Oral tolerisation of arthritic patients by administration of type II collagen has also been shown to be effective clinically and therapeutic effects have been reported with small (less than 100mg) daily doses of type II collagen antigens. Studies using rheumatoid and juvenile rheumatoid arthritis patients confirmed the efficacy and safety of low daily oral doses of type II collagen derived from chick sterna (Trentham D, et al. Effects of oral administration of type II collagen on rheumatoid arthritis. *Science*, **261**: 1727-1730, 1993) (Barnett *et al*, A pilot study of oral type II collagen in the treatment of juvenile rheumatoid arthritis. *Arthritis. Rheum.* **39**:623-628, 1996). Other studies have indicated that cartilage collagens obtained from bovine sources were less effective than those prepared from chick cartilage.

Unfortunately, some studies have found that high doses of type II collagen may in fact exacerbate disease since, as already indicated, this cartilage derived antigen is also an arthritogen and it is difficult to accurately determine how much of this antigen would be effective or detrimental to the arthritic process. With regard to other cartilage collagens types X, XI are arthritogenic, while type IX collagen has been reported to be not as effective as type II collagen as a tolerant in some animal arthritis models (Lu S *et al*, Different therapeutic and bystander effects by intranasal administration of

homologous type II and type IX collagens on the collagen- induced arthritis and Pristane-induced arthritis in rats. Clin Immunol. 90:119-127, 1999).

In another study using recombinantly produced in-tact native type IX collagen it was found that when it was given orally to B10 congenic mice this collagen was able to ameliorate the arthritis produced by prior inoculation with type II collagen (collagen induced arthritis, CIA). The recombinant type IX collagen was also tested for immunogenicity in other murine models and unlike type II collagen, it failed to induce overt arthritis in mice immunized with this protein (Myers L K *et al*, Immunogenicity of recombinant Type IX collagen in murine collagen-induced arthritis. Arthritis Rheum. 46:1086-1093, 2002).

The discrepancy between the Lu et al (1999) and Myers et al (2002) may be explained by differences in the purity and molecular size of the type IX collagen preparations. Recombinant technology is considered the only means of obtaining pure native type IX collagen since very little can be extracted from the cartilage matrix without using proteolysis as it is covalently bound to the type II collagen fibrils. The most common proteinase used to extract type IX collagen from cartilages is pepsin which is a commercial preparation generally derived from porcine stomach mucosa. Pepsin is not present in cartilage. This enzyme hydrolyses the non-collagenous domains of the type IX molecule releasing the native COL1, COL2, and COL3 triple helical segments which are isolated from the mixture by precipitation leaving the partially degraded non-helical NC domains in solution.

The endogenous proteinases responsible for the normal turnover of type IX collagen in cartilaginous tissues are presently unknown. However, the matrix metalloproteinase (MMP) family, the serine proteinases and cysteine proteinases are all known to degrade type IX collagen *in vitro* in both the helical (COL) and non-helical (NC) domains.

SUMMARY OF INVENTION

In work leading up to the present invention, the inventor sought to recover connective tissue derived polypeptides having anti-arthritis or anti-inflammatory activity. The inventor found that polypeptides produced by autolysis of connective tissue and having a molecular weight of less than 30,000Da had anti-arthritis or anti-inflammatory activity.

The inventor also found that administration of a composition comprising one or more connective tissue derived polypeptides having a molecular weight of less than

30,000Da, tolerised individuals to antigenic components of cartilage and prevented the appearance of symptoms of arthritis.

5 Analysis of the polypeptides using proteomic techniques showed that fragments of the polypeptide produced by their tryptic digestion had strong identity with the NC4 domain of collagen type IX alpha 1 chain.

Accordingly, the present invention relates to the use of a polypeptide comprising a collagen type IX alpha 1 chain NC4 domain or biologically active fragment thereof having anti-arthritis or anti-inflammatory activity for the treatment or prevention of
10 arthritis or other degenerative disease of the musculoskeletal system in an individual.

In a first aspect the invention provides a pharmaceutical composition for treating or preventing arthritis or other degenerative disease in an individual, said composition comprising a polypeptide comprising a collagen type IX alpha 1 chain NC4 domain or biologically active fragment thereof having anti-arthritis or anti-inflammatory activity
15 in combination with a pharmaceutically acceptable carrier. In a preferred embodiment, the polypeptide has a molecular weight of less than 30,000Da and/or an amino acid length of less than 250 amino acids. In a further preferred embodiment, the polypeptide or biologically active fragment thereof is derived from a mammal.

In another aspect the invention provides a pharmaceutical composition for
20 inducing tolerance in an individual to at least one antigenic component of cartilage, said composition comprising a polypeptide comprising collagen type IX alpha 1 chain NC4 domain or biologically active fragment thereof having anti-arthritis or anti-inflammatory activity in combination with a pharmaceutically acceptable carrier. In a preferred embodiment the collagen type IX alpha 1 chain NC4 domain polypeptide has
25 a molecular weight of less than 30,000Da or an amino acid length of less than 250 amino acids.

In one example, the collagen type IX alpha 1 chain NC4 domain comprises

- (i) an amino acid sequence as provided in SEQ ID NO 1, SEQ ID NO 14, SEQ ID NO 16, or SEQ ID NO 18,
- 30 (ii) an amino acid sequence which is at least 70% identical to either SEQ ID NO 1, SEQ ID NO 14, SEQ ID NO 16, or SEQ ID NO 18, or
- (iii) a biologically active fragment of (i) or (ii).

Preferably, the collagen type IX alpha 1 chain NC4 domain comprises an amino acid sequence which is at least 75%, preferably 80%, 85%, 90% or 95% identical to any
35 one of SEQ ID NO 1, SEQ ID NO 14, SEQ ID NO 16, or SEQ ID NO 18.

In one example, the collagen type IX alpha 1 chain NC4 domain comprises:

(i) an amino acid sequence as provided in residues 21-182 of SEQ ID NO 1; residues 60-181 of SEQ ID NO 1; residues 72-181 of SEQ ID NO 1, residues 98-182 of SEQ ID NO 1, or residues 123-182 of SEQ ID NO 1; or

- (ii) an amino acid sequence as provided in residues Ala1-Arg245 of SEQ ID NO 14; residues Pro6-Arg245 of SEQ ID NO 14, residues Pro6-Asp192 of SEQ ID NO 14, residues Pro6-Arg186 of SEQ ID NO 14, residues Pro6-Pro185 of SEQ ID NO 14, residues Pro6-Arg73 of SEQ ID NO 14, or residues Pro85-Pro185 of SEQ ID NO 14.

In another example, the collagen type IX alpha 1 chain NC4 domain comprises at least one of SEQ ID NOs 2-11.

- 10 In a preferred embodiment, inducing tolerance in the individual prevents at least one symptom of arthritis or other musculoskeletal degenerative condition in the individual.

- As used herein to "prevent at least one symptom" refers to defending against or inhibiting a symptom, delaying the appearance of a symptom, reducing the severity of the development of a symptom, and/or reducing the number or type of symptoms suffered by an individual, as compared to not administering a pharmaceutical composition comprising a polypeptide of the invention. Accordingly, throughout this description, it will be understood that any clinically or statistically significant attenuation of even one symptom of a musculoskeletal degenerative condition pursuant to the treatment according to the present invention is within the scope of the invention.

The present invention also provides a method of inducing tolerance in an individual to at least one antigenic component of cartilage comprising administering the individual with an effective amount of the pharmaceutical composition according to the first aspect of the invention.

- 25 Preferably the method of inducing tolerance in the individual prevents the onset of the musculoskeletal degenerative condition.

Accordingly, the invention provides a method for preventing a musculoskeletal degenerative condition in an individual comprising administering a pharmaceutically effective amount of a composition according to the first aspect to the individual.

- 30 Further, the invention provides a method for preventing an autoimmune response to at least one antigenic component of cartilage comprising administering a composition according to the first aspect of the individual.

- In related aspects, the invention further provides for use of a polypeptide comprising a collagen type IX alpha 1 chain NC4 domain or biologically active fragment having anti-arthritis or anti-inflammatory activity in combination with a pharmaceutically acceptable carrier in the manufacture of a medicament for inducing

tolerance to at least one antigenic component of cartilage or for preventing a musculoskeletal degenerative condition in an individual.

Preferably, the pharmaceutical composition of the present invention is one which prevents at least one symptom of arthritis, such as for example inflammation, joint
5 tenderness, joint swelling, joint stiffness, restricted mobility, or strength reduction, when administered to a naïve individual.

In one example, the individual is a naïve individual. By "naïve individual" is meant that preferably the individual does not present two or more symptoms of a musculoskeletal degenerative condition, more preferably the individual does not present
10 a symptom of a musculoskeletal degenerative condition. This may be prior to or during or post the course of a musculoskeletal disease.

In a further aspect, the present invention provides methods for recovering polypeptides having a molecular weight of less than 30,000Da from connective tissue wherein connective tissue particles are subjected to autolysis in the presence of an
15 autolysis medium such that a mixture of glycosaminoglycan peptides and polypeptides are released from the connective tissue particles into the autolysis medium. The process of inducing autolysis has previously been described in PCT/AU03/00061 (in the name of the Applicant), which is incorporated herein by reference. According to the invention, polypeptides are recovered from the medium and are separated according to
20 size. The invention also provides methods for separating and identifying the recovered polypeptides according to their size and charge.

Accordingly, in one example the method for preparing a polypeptide having anti-arthritis or anti-inflammatory activity comprises isolating a mixture comprising a GAG-peptide and a polypeptide having a molecular weight of less than 30,000Da by autolysis
25 from connective tissue, separating the GAG-peptide from the polypeptide, and recovering the polypeptide.

In a related example, the present invention provides a method for preparing a polypeptide having anti-arthritis or anti-inflammatory activity, the method comprising

- (i) incubating a connective tissue in an autolysis medium that provides a buffered
30 pH range of between about pH 2.5 and about pH 8.5 for a time and under conditions sufficient to release a GAG-peptide and a polypeptide having a molecular weight of less than 30,000Da,
- (ii) recovering a mixture comprising the GAG-peptide and polypeptide from the autolysis medium;
- 35 (iii) separating the polypeptide from the GAG-peptide; and
- (iv) recovering the polypeptide having a molecular weight of less than 30,000Da.

Any well known techniques such as for example, chromatography, ion exchange techniques, gel filtration (eg. diafiltration or ultrafiltration), gel electrophoresis (eg. one dimensional or two dimensional) or any other method of separating and/or recovering polypeptides according to their size and molecular weight, or combination thereof, can be used to recover the polypeptide from the mixture.

A combination of the same or similar techniques may be used and may be repeated. In this way, fractions of polypeptides of different molecular weight ranges may be obtained and individual polypeptides can also be recovered.

Polypeptides recovered by the method of the invention are connective tissue derived polypeptides. The present invention clearly contemplates that the recovered polypeptides may comprise mixtures of polypeptides or individual polypeptides.

The inventor has found that the recovered polypeptides and mixtures thereof have enhanced and/or different pharmacological activities to the GAG-peptide/polypeptide mixture. The polypeptides according to the present invention are those connective-tissue derived polypeptides having anti-arthritis or anti-inflammatory activity. In one embodiment, a polypeptide of the invention reduces rear paw inflammation in rats with collagen induced arthritis. In another embodiment, a polypeptide of the invention decreases tail inflammation in rats with collagen induced arthritis. In another embodiment, a polypeptide of the invention decreases fore paw inflammation in rats with collagen induced arthritis. In yet another embodiment, a polypeptide of the invention decreases weight loss in rats with collagen induced arthritis.

Accordingly, another example of the present invention provides a connective tissue derived polypeptide, having a molecular weight of less than 30,000Da which is obtainable by the method of the invention, and having anti-arthritis or anti-inflammatory activity.

For example, the invention provides a connective tissue derived polypeptide having a molecular weight of less than 30,000Da which is obtainable by:

- (i) incubating a connective tissue in an autolysis medium that provides a buffered pH range of between about pH 2.5 and about pH 8.5 for a time and under conditions sufficient to release a GAG-peptide and a polypeptide having a molecular weight of less than 30,000Da,
- (ii) recovering a mixture comprising the GAG-peptide and polypeptide from the autolysis medium;
- (iii) separating the polypeptide from the GAG-peptide; and
- (iv) recovering the polypeptide having a molecular weight of less than 30,000Da.

In one example, the recovered polypeptide comprises a non-collagenous region-4 (NC4) of the collagen type IX $\alpha 1$ chain, or biologically active fragment thereof.

The effects observed for the polypeptides of the invention on rats with collagen induced arthritis also provide application for the polypeptides in the treatment, protection and restoration of connective tissues in inflammatory and degenerative tissue diseases such as rheumatoid arthritis and osteoarthritis in all animals. Preferably, the polypeptides of the present invention prevent antigen driven autoimmune diseases in animals. In another preferred embodiment, polypeptides of the invention reduce symptoms associated with antigen driven autoimmune diseases in animals.

Accordingly, it is to be understood that the forgoing examples apply *mutatis mutandis* to each and every aspect of the invention.

Accordingly, the invention provides a pharmaceutical composition for treating or preventing arthritis or other musculoskeletal degenerative disease in an individual, said composition comprising one or more connective tissue derived polypeptides having anti-arthritis or anti-inflammatory, wherein said polypeptide is obtainable by a method comprising isolating a mixture comprising a GAG-peptide and a polypeptide having a molecular weight of less than 30,000Da by autolysis from connective tissue, separating the GAG-peptide from the polypeptide, and recovering the polypeptide.

The invention also provides a pharmaceutical composition for inducing tolerance in an individual to at least one antigenic component of cartilage, said composition comprising one or more connective tissue derived polypeptides having anti-arthritis or anti-inflammatory, wherein said polypeptide is obtainable by a method comprising isolating a mixture comprising a GAG-peptide and a polypeptide having a molecular weight of less than 30,000Da by autolysis from connective tissue, separating the GAG-peptide from the polypeptide, and recovering the polypeptide having a molecular weight of less than 30,000Da.

Preferably, inducing tolerance in the individual prevents at least one symptom of a musculoskeletal degenerative disease in the individual.

In another example, the present invention provides a method for preventing a musculoskeletal degenerative condition in an individual comprising administering the individual with an effective amount of a pharmaceutical composition comprising one or more connective tissue derived polypeptides having anti-arthritis or anti-inflammatory, wherein said polypeptide is obtainable by a method comprising isolating a mixture comprising a GAG-peptide and a polypeptide having a molecular weight of less than 30,000Da by autolysis from connective tissue, separating the GAG-peptide from the

polypeptide, and recovering the polypeptide having a molecular weight of less than 30,000Da.

5 In another example, the present invention provides a method for preventing autoimmune response in an individual to at least one antigenic component of cartilage comprising administering the individual with an effective amount of a pharmaceutical composition comprising one or more connective tissue derived polypeptides having anti-arthritic or anti-inflammatory, wherein said polypeptide is obtainable by a method comprising isolating a mixture comprising a GAG-peptide and a polypeptide having a molecular weight of less than 30,000Da by autolysis from connective tissue, separating
10 the GAG-peptide from the polypeptide, and recovering the polypeptide having a molecular weight of less than 30,000Da.

The present invention further provides a method of inducing cartilage formation in an individual, comprising administering to the individual an effective amount of a connective tissue derived polypeptide according to the invention and having anti-
15 arthritic or anti-inflammatory activity, wherein said polypeptide is obtainable by a method comprising isolating a mixture comprising a GAG-peptide and a polypeptide having a molecular weight of less than 30,000Da by autolysis from connective tissue, separating the GAG-peptide from the polypeptide, and recovering the polypeptide having a molecular weight of less than 30,000Da.

20 In other related examples, the present invention provides for use of one or more connective tissue derived polypeptides having anti-arthritic or anti-inflammatory, in the preparation of a medicament for the treatment or prevention of arthritis or other musculoskeletal disease in a subject, wherein said polypeptide is obtainable by the method comprising isolating a mixture comprising a GAG-peptide and a polypeptide
25 having a molecular weight of less than 30,000Da by autolysis from connective tissue, separating the GAG-peptide from the polypeptide, and recovering the polypeptide.

In one example the invention provides for the use of one or more connective tissue derived polypeptides having anti-arthritic or anti-inflammatory, in the preparation of a medicament for tolerising an individual to at least one antigenic component of
30 cartilage, wherein said polypeptide is obtainable by a method comprising isolating a mixture comprising a GAG-peptide and a polypeptide having a molecular weight of less than 30,000Da by autolysis from connective tissue, separating the GAG-peptide from the polypeptide, and recovering the polypeptide having a molecular weight of less than 30,000Da.

35 It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific

embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

5 DETAILED DESCRIPTION OF THE FIGURES

Figure 1 is a schematic representation of the Human type IX collagen molecule showing the 3 α chains which constitute the heteropolymer and their collagenous (COL) and non-collagenous (NC) domains. The COL regions are triple helical while the NC domains are non-helical. Cysteine residues in the NC3 and NC1 Regions allow
10 disulfide bond interactions. NC4 is only present on the $\alpha 1$ (IX) chain and is overall positively charged allowing it to interact with polyanionic glycosaminoglycans in the extracellular matrix. A single chondroitin sulfate chain is attached, via a serine residue, to the NC3 region of the $\alpha 2$ (IX) chain in the native molecule.

15

Figure 2 is a schematic diagram of the methods used for the separation and sub-fractionation of the glycosaminoglycan peptide and polypeptide mixture (eg calcium peptacan (CaP)) into purified GAG-peptides and polypeptides using ion exchange media.

20

Figure 3 is a photographic representation of the SDS-PAGE 1-D electrophoresis of the proteins/polypeptides isolated from the glycosaminoglycan-peptide and polypeptide mixture (CaP) using the ion-exchange schema shown in Figure 2.

25 Figure 4 is a photographic representation of the SDS-PAGE 2-D electrophoresis of the proteins/polypeptides isolated from the glycosaminoglycan-peptide and polypeptide mixture (CaP) using the ion-exchange schema shown in Figure 2. The majority of the spots resolved by this procedure were isolated and subjected to trypsin digestion sequence analysis using Matrix Assisted Laser Desorption Ionisation mass spectrometry
30 (MALDI-MS).

35

Figure 5 is summary of the toleragenic and prophylactic/therapeutic protocols used to evaluate the antiarthritic effects of the polypeptides INR-195 and INR-126 in the rat collagen induced arthritis (CIA) model.

Figure 6 show representative photomicrographs of stained histological sections, prepared and stained using standard methods, of hind-paw joints from normal and the untreated rat collagen induced arthritis (CIA) model at day 18 showing the extent of inflammatory cell invasion and destruction of tendons, cartilage and bone.

5

Figure 7 shows representative photomicrographs of stained histological sections, prepared and stained using standard methods, of hind-paw joints from normal and the rat collagen induced arthritis (CIA) model at day 18 of animals treated orally with the polypeptides INR-126 (20mg/kg) and INR195 (20mg/kg) using the toleragenic or prophylactic/therapeutic protocols. Note the reduction of the inflammatory cell invasion and destruction of tendons, cartilage and bone compared to the untreated groups shown in Figure 6.

10

DETAILED DESCRIPTION OF THE INVENTION

15

I. Autolysis

Connective tissue is an animal tissue that supports organs, fills the spaces between them, and forms tendons and ligaments. The term "tissue" as used herein refers to a group of similarly specialised cells that perform a common function. As used herein, tissue is intended to include an organ composed of a given tissue and to the cells, individually or collectively, that compose the tissue.

20

In one embodiment, the connective tissue is a cartilage. In another embodiment, the connective tissue is non-cartilage material eg. lung, skin, bone, ligament or tendon.

Preferably the cartilage is tracheal, articular, auricular, nasal, sternal, rib skeletal, or antler cartilage. Cartilage may, however, be any type of cartilage.

25

Connective tissue may be obtained from any animal having connective tissue.

In one embodiment, connective tissue is selected from any one of the following: human, bovine, ovine, porcine, equine, avian, cervine and piscine species. Preferably the connective tissue is bovine, ovine, porcine, cervine, shark or equine.

30

In one embodiment tissues from young animals are preferable eg a calf. In an alternate embodiment a more mature animal is preferred.

The connective tissue may be treated and washed as required by methods known in the art to remove any adhering soft tissues. In one embodiment the connective tissue

is reduced to a particle size. In an alternate embodiment the connective tissue is not reduced to a particle size.

The connective tissue can be reduced to a particle size by means including, but not limited to, mincing, dicing, grinding and the like. In one embodiment particle diameter is less than about 5mm, preferably less than about 4mm, more preferably less than about 3mm. Most preferably, the particle diameter is about 0.1mm to about 3mm.

The terms “incubate” or “incubating” mean to maintain (a chemical or biochemical system) under specific conditions in order to promote a particular reaction.

As used herein the term “autolysis” refers to the digestion of cellular components by endogenous hydrolases and proteinases released from lysosomes or associated with the cell and its pericellular matrix following cell death, causing self digestion of tissue. A person skilled in the art will appreciate that the rate of autolysis will vary with many factors including pH, temperature, concentration, tissue type, tissue particle size and time of incubation.

The term “buffer” refers to a compound, usually a salt, which, when dissolved in an aqueous medium serves to maintain the free hydrogen ion concentration of the solution within a certain pH range, when hydrogen ions are added or removed from the solution. A salt or solution is said to have a “buffering capacity” or to buffer the solution over such a range, when it provides this function. Generally a buffer will have adequate buffering capacity over a range that is within ± 1 pH unit of its pK.

In one embodiment the salt is a monovalent salt. Preferably the monovalent salt is selected from any one or more of hydrogen, sodium, potassium, or ammonium. In an alternate embodiment the salt is not a monovalent salt. In another embodiment the salt is a divalent salt selected from any one or more of calcium, magnesium, copper, or zinc. Most preferably the salt is calcium or magnesium.

In one embodiment the pH is in the range of about 2.5 to about 8.5, preferably about 3.5 to about 8.0, more preferably about 4 to about 7 and most preferably about 4.5 to about 7.

The term “condition” refers to other factors which affect the rate, efficiency and amount of autolysis, such as, for example, temperature and time.

In one embodiment the temperature conditions for carrying out the step of autolysis is in the range of from about 20°C to about 45°C, preferably about 25°C to about 45°C, more preferably about 32°C to about 45°C, more preferably about 32°C to about 40°C most preferably about 37°C.

In one embodiment, the autolysis takes up to 48 hours, preferably up to 36 hours, preferably up to 24, preferably up to 16 hours, more preferably 16-24 hours.

In a preferred embodiment, cartilage particles of size 1-3mm are subject to autolysis in an aqueous medium at a pH of 4-5 and temperature of 32-45°C for 16-24 hours.

Glycosaminoglycan (GAG) refers to the polysaccharide chains of proteoglycans, which are composed of repeating disaccharide units containing a derivative of an amino sugar (either glucosamine or galactosamine) glycosidically linked to glucuronic or iduronic acid. The most common derivatives being O-sulfated esters substituted in the 4 or 6 positions of the N-acetylated glucosamine or galactosamine rings.

Examples of GAGs include hyaluronic acid (hyaluronan) (which is non-sulfated), chondroitin sulfate, keratan sulfate and heparan sulfate.

The terms "protein", "polypeptide", or "peptide", when used herein are interchangeable and refer to amino acids in a polymeric form of any length.

GAG-peptides and polypeptides can be recovered from the autolysis medium with well known methods. For example, in one embodiment, the residual tissue particles are removed by filtration from the autolysis media and the mixture of GAG-peptide complexes and polypeptides recovered from the supernatant. In another embodiment, the residual tissue particles are not removed from the autolysis medium.

In one embodiment, the supernatant is neutralised by addition of an alkaline solution containing a cation.

In one embodiment the supernatant is freeze dried. In an alternate embodiment the supernatant is not freeze dried.

Alternatively the mixture of GAG-peptide and polypeptide is recovered from the autolysis medium or supernatant by precipitation with excess quantities of acetone, or aliphatic alcohols, such as, for example, ethanol or methanol. In another embodiment, the mixture of GAG-peptide and polypeptide is recovered from the autolysis medium or supernatant by the formation of water insoluble complexes with quaternary ammonium salts such as cetyl pyridinium, chloride. In another embodiment the mixture of GAG-peptide and polypeptide are recovered from the autolysis medium or supernatant by separation using size exclusion or ion-exchange or other forms of column chromatography or membrane filtration technology.

2. Separating and recovering the polypeptides of the invention

Following recovery of the mixture of the GAG-peptide and polypeptide, the polypeptide and GAG-peptide can be separated by methods well known in the art.

Preferably, the mixture of the GAG-peptide and the polypeptide is subjected to an ion exchange technique. In one embodiment the mixture of the GAG-peptide and

the polypeptide is subjected to ion exchange solid phase media. In one embodiment the solid phase media is DEAE sepharose. In a preferred embodiment, the solid phase media is pre-swollen DEAE-Sepharose-6B.

Recovery of the polypeptide refers to any well known separation technique. In one embodiment the polypeptide can be recovered by, for example, chromatography, ion exchange techniques, gel filtration (eg. diafiltration or ultrafiltration), gel electrophoresis (eg. one dimensional or two dimensional) or any other method of separating polypeptides according to their size and molecular weight, or combination thereof, and which is capable of recovering polypeptides having a molecular weight of less than 30,000Da.

A combination of the same or similar separation techniques may be used and may be repeated. In this way, fractions of polypeptides of different molecular weight ranges may be obtained and individual polypeptides can also be recovered. It will be understood that separation of polypeptides according to size and molecular may be performed in any order.

Accordingly, in one example the recovered polypeptides are subjected to a separation technique to recover polypeptides having a molecular weight of greater than 1,000Da. The recovered polypeptides having a molecular weight of greater than 1,000Da are subjected to a separation technique to recover polypeptides having a molecular weight of less than 30,000Da. Accordingly, in one example the polypeptides have a molecular weight of less than 30,000Da and greater than 1,000Da.

In another example, the recovered polypeptides are subjected to a separation technique to recover polypeptides having a molecular weight of greater than 1,000Da and then subjected to a separation technique to recover polypeptides having a molecular weight of greater than 10,000Da.

Accordingly, examples of the invention relate to the recover of polypeptides having a molecular weight of less than 30,000Da, less than 30,000Da and greater than about 1,000Da, and less than 30,000 and greater than 10,000.

In a further embodiment, the present invention comprises separating the one or more recovered polypeptides to recover individual polypeptides. Separation can be performed according to any well known techniques such as for example chromatography, one dimensional gel electrophoresis, two dimensional electrophoresis or the like.

The inventors have further analysed and identified the individual polypeptides separated by the method of the present invention.

Polypeptides recovered by the method of the invention are connective tissue derived polypeptides. The inventors have found that the recovered polypeptides and mixtures thereof have enhanced and/or different pharmacological activities to the GAG-peptide/polypeptide mixtures.

5 Accordingly, the present invention provides a connective tissue derived polypeptide, obtainable by the method of the invention, having anti-arthritis or anti-inflammatory activity. In one embodiment, polypeptides of the invention and mixtures thereof reduce rear paw inflammation in rats with collagen induced arthritis. In another
10 embodiment, polypeptides of the invention and mixtures thereof decrease tail inflammation in rats with collagen induced arthritis. In another embodiment, polypeptides decrease fore paw inflammation in rats with collagen induced arthritis. In yet another embodiment, polypeptides of the invention and mixtures thereof decrease weight loss in rats with collagen induced arthritis.

As used herein the term "derived" shall be taken to indicate that a specified
15 integer may be obtained from a source, albeit not necessarily directly from that source.

In an alternate embodiment, the polypeptides of the present invention are connective tissue derived polypeptides obtainable by the methods of the present invention having a molecular weight in the range of less than about 30,000Da and having anti-arthritis or anti-inflammatory.

20 In an alternate embodiment, the polypeptides of the present invention are connective tissue derived polypeptides obtainable by the methods of the present invention having a molecular weight in the range of about 1,000Da and about 30,000Da and having anti-arthritis or anti-inflammatory.

25 In an alternate embodiment, the polypeptides of the present invention are connective tissue derived polypeptides obtainable by the methods of the present invention having a molecular weight in the range of about 10,000Da and about 30,000Da and having anti-arthritis or anti-inflammatory.

30 In another embodiment, the polypeptides of the present invention are connective tissue derived polypeptides obtainable by the methods of the present invention, having a molecular weight in the range of about 25,000Da and about 30,000Da and having anti-arthritis or anti-inflammatory.

Mixtures of polypeptides which have a molecular weight in a desired range are clearly contemplated.

35 In another embodiment, individual polypeptides obtainable by the methods of the invention having anti-arthritis or anti-inflammatory are contemplated. In one

example the connective tissue derived polypeptides of the present invention have a molecular weight of about 27,000Da.

In a preferred example, the present invention provides a connective tissue derived polypeptide having a molecular weight of about 10,000Da to about 30,000Da, having anti-arthritis or anti-inflammatory and selected from the group consisting of:

- (a) a connective tissue derived polypeptide having an isoelectric point (pI) of about 6 to about 6.5, and more preferably a pI value of about 6.3 as determined by isoelectric focussing.
- (b) a connective tissue derived polypeptide having an isoelectric point (pI) of about 6.5 to about 7, and more preferably a pI value of about 6.8 as determined by isoelectric focussing
- (c) a connective tissue derived polypeptide having an isoelectric point (pI) of about 7.5 to about 8.5, and more preferably a pI value of about 7.8 as determined by isoelectric focussing
- (d) a connective tissue derived polypeptide having an isoelectric point (pI) of about 8 to about 8.5, and more preferably a pI value of about 8.2 as determined by isoelectric focussing
- (e) a connective tissue derived polypeptide having an isoelectric point (pI) of about 8 to about 8.5, and more preferably a pI value of about 8.3 as determined by isoelectric focussing
- (f) a connective tissue derived polypeptide having an isoelectric point (pI) of about 8.3 to about 8.8, and more preferably a pI value of about 8.6 as determined by isoelectric focussing
- (g) a connective tissue derived polypeptide having an isoelectric point (pI) of about 8.8 to about 9.5, and more preferably a pI value of about 9.1 as determined by isoelectric focussing
- (h) a connective tissue derived polypeptide having an isoelectric point (pI) of about 6 to about 6.5, and more preferably a pI value of about 6.2 as determined by isoelectric focussing
- (i) a connective tissue derived polypeptide having an isoelectric point (pI) of about 6.8 to about 7.5, and more preferably a pI value of about 7.2 as determined by isoelectric focussing

Individual polypeptides of the invention have been identified as fragments of known proteins. Peptides of up to about 30 amino acids were produced by subjecting a polypeptide to trypsin digestion and then to Matrix Assisted Laser Desorption

Ionisation (MALDI) mass spectrometry. The peptides have been compared to known proteins provided in reference databases.

Accordingly, in another embodiment, the present invention provides an isolated polypeptide obtainable by the method of the invention comprising the sequences and %
 5 match with known proteins as disclosed in Figure 4, wherein the polypeptide or polypeptide fragment has anti-arthritic or anti-inflammatory.

Preferably, the connective tissue derived polypeptide in paragraph (a) *supra* comprises one or more of the following sequences following trypsin digestion:

- (K)LGNNV DFR(I) (SEQ ID NO. 4)
 10 (R)IESLP IKPR(G) (SEQ ID NO. 5)
 (R)HLYPN GLPEE YSFLT TFR(M) (SEQ ID NO. 8)
 (K)IMIGV ER(S) (SEQ ID NO. 3)
 (R)SSATL FVDCN R(I) (SEQ ID NO. 11)

Preferably, the connective tissue derived polypeptide in paragraph (b) *supra* comprises one or more of the following sequences following trypsin digestion:

- (K)SVSFS YK(G) (SEQ ID NO. 2)
 (K)IMIGV ER(S) (SEQ ID NO. 3)
 (K)LGNNV DFR(I) (SEQ ID NO. 4)
 (R)IESLP IKPR(G) (SEQ ID NO. 5)
 20 (K)HWSIW QIQDS SGK(E) (SEQ ID NO. 6)
 (R)IGQDD LPGFD LISQF QIDK(A) (SEQ ID NO. 7)
 (R)HLYPN GLPEE YSFLT TFR(M) (SEQ ID NO. 8)
 (K)GLDGS LQTAA FSNLP SLFDS QWHK(I) (SEQ ID NO. 9)
 (K)IMIGV ER(S) (SEQ ID NO. 10)
 25 (R)SSATL FVDCN R(I) (SEQ ID NO. 11)

Preferably, the connective tissue derived polypeptide in paragraph (c) *supra* comprises one or more of the following sequences following trypsin digestion:

- (K)SVSFS YK(G) (SEQ ID NO. 2)
 (K)IMIGV ER(S) (SEQ ID NO. 3)
 30 (K)LGNNV DFR(I) (SEQ ID NO. 4)
 (R)IESLP IKPR(G) (SEQ ID NO. 5)
 (K)HWSIW QIQDS SGK(E) (SEQ ID NO. 6)
 (R)IGQDD LPGFD LISQF QIDK(A) (SEQ ID NO. 7)
 (R)HLYPN GLPEE YSFLT TFR(M) (SEQ ID NO. 8)
 35 (K)GLDGS LQTAA FSNLP SLFDS QWHK(I) (SEQ ID NO. 9)
 (K)IMIGV ER(S) (SEQ ID NO. 10)

(R)SSATL FVDCN R(I) ([SEQ ID NO. 11](#))

Preferably, the connective tissue derived polypeptide in paragraph (d) *supra* comprises one or more of the following sequences following trypsin digestion:

(K)SVSFS YK(G) ([SEQ ID NO. 2](#))

5 (K)IMIGV ER(S) ([SEQ ID NO. 3](#))

(K)LGNNV DFR(I) ([SEQ ID NO. 4](#))

(R)IESLP IKPR(G) ([SEQ ID NO. 5](#))

(K)HWSIW QIQDS SGK(E) ([SEQ ID NO. 6](#))

(R)HLYPN GLPEE YSFLT TFR(M) ([SEQ ID NO. 8](#))

10 (K)GLDGS LQTAA FSNLP SLFDS QWHK(I) ([SEQ ID NO. 9](#))

(R)SSATL FVDCN R(I) ([SEQ ID NO. 11](#))

Preferably, the connective tissue derived polypeptide in paragraph (e) *supra* comprises one or more of the following sequences following trypsin digestion:

(K)LGNNVDFR(I) ([SEQ ID NO. 4](#))

15 (R)IESLPIKPR(G) ([SEQ ID NO. 5](#))

(R)IGQDD LPGFD LISQF QIDK(A) ([SEQ ID NO. 7](#))

(R)HLYPN GLPEE YSFLT TFR(M) ([SEQ ID NO. 8](#))

(R)SSATL FVDCN R(I) ([SEQ ID NO. 11](#))

20 Preferably, the connective tissue derived polypeptide in paragraph (f) *supra* comprises one or more of the following sequences following trypsin digestion:

(K)SVSFS YK(G) ([SEQ ID NO. 2](#))

(K)IMIGV ER(S) ([SEQ ID NO. 3](#))

(K)LGNNV DFR(I) ([SEQ ID NO. 4](#))

(R)IESLP IKPR(G) ([SEQ ID NO. 5](#))

25 (K)HWSIW QIQDS SGK(E) ([SEQ ID NO. 6](#))

(R)IGQDD LPGFD LISQF QIDK(A) ([SEQ ID NO. 7](#))

(R)HLYPN GLPEE YSFLT TFR(M) ([SEQ ID NO. 8](#))

(K)IMIGV ER(S) ([SEQ ID NO. 10](#))

(R)SSATL FVDCN R(I) ([SEQ ID NO. 11](#))

30 Preferably, the connective tissue derived polypeptide in paragraph (g) *supra* comprises one or more of the following sequences following trypsin digestion:

(K)LGNNV DFR(I) ([SEQ ID NO. 4](#))

(R)IESLP IKPR(G) ([SEQ ID NO. 5](#))

(R)IGQDD LPGFD LISQF QIDK(A) ([SEQ ID NO. 7](#))

35 (R)HLYPN GLPEE YSFLT TFR(M) ([SEQ ID NO. 8](#))

(R)SSATL FVDCN R(I) ([SEQ ID NO. 11](#))

Preferably, the connective tissue derived polypeptide in paragraph (h) *supra* comprises one or more of the following sequences following trypsin digestion:

- (K)SVSFS YK(G) (SEQ ID NO. 2)
- (K)IMIGV ER(S) (SEQ ID NO. 3)
- 5 (K)LGNNV DFR(I) (SEQ ID NO. 4)
- (R)IESLP IKPR(G) (SEQ ID NO. 5)
- (K)HWSIW QIQDS SGK(E) (SEQ ID NO. 6)
- (R)IGQDD LPGFD LISQF QIDK(A) (SEQ ID NO. 7)
- (R)HLYPN GLPEE YSFLT TFR(M) (SEQ ID NO. 8)
- 10 (K)IMIGV ER(S) (SEQ ID NO. 10)
- (R)SSATL FVDCN R(I) (SEQ ID NO. 11)

Preferably, the connective tissue derived polypeptide in paragraph (i) *supra* comprises one or more of the following sequences following trypsin digestion:

- (K)SVSFS YK(G) (SEQ ID NO. 2)
- 15 (K)IMIGV ER(S) (SEQ ID NO. 3)
- (K)LGNNV DFR(I) (SEQ ID NO. 4)
- (R)IESLP IKPR(G) (SEQ ID NO. 5)
- (K)HWSIW QIQDS SGK(E) (SEQ ID NO. 6)
- (R)IGQDD LPGFD LISQF QIDK(A) (SEQ ID NO. 7)
- 20 (R)HLYPN GLPEE YSFLT TFR(M) (SEQ ID NO. 8)
- (K)IMIGV ER(S) (SEQ ID NO. 3)
- (R)SSATL FVDCN R(I) (SEQ ID NO. 11).

Preferably, the connective tissue derived polypeptide in paragraphs (a)-(i) *supra* comprises an amino acid sequence having substantial identity to the sequence of Type
 25 IX collagen alpha 1 chain NC4 domain as depicted in Table 1 below or a homologue or derivative thereof.

Table 1
Physical Characteristics of Protein fragments found in Calcium Peptacan after ion-exchange treatment and 2D electrophoresis.

Fragment ID#	Estimated isoelectric point	Estimated Molecular Weight
1	4.0	74kDa
2	4.1	65kDa
3	3.9	50kDa
(this band has now been shown to correspond to fragments from 2 or 3 proteins identified as bovine COMP and either bovine alpha-1 antiprotease inhibitor or Endopin-1)		
4	3.7	45kDa
5	3.4	40kDa
6	4.6	50kDa
7	6.3	67kDa
8	6.1	65kDa
9	6.3	60kDa
10	6.3	38kDa
11	6.0	30kDa
12	6.4	25kDa
13	6.8	22kDa
14	7.8	20kDa
15	8.2	18kDa
16	8.3	19kDa

17	8.6	20kDa
18	9.1	19kDa
19	5.3	12kDa
20	6.2	22kDa
21	7.2	21kDa

Table 1 shows the physical characteristics (MW and pI) of protein fragments polypeptides found in Calcium Peptacan after ion-exchange treatment and 2D electrophoresis as described in Figure 4.

5

3. Polypeptides

The present inventors have substantially purified and established the identity of the type IX collagen alpha 1 chain polypeptide which is produced during the autolytic processing of bovine cartilage matrix.

Also incorporated herein are amino sequences for collagen type IX alpha 1 NC4 domain derived from human, chick and rat connective tissue. Amino acid sequence comparisons of the bovine-chick NC4 domain polypeptides (see Table 2 below), and bovine-human NC4 domain polypeptides (see Table 3 below) show sequence overlap.

Table 2 below shows the amino acid sequence of the NC4 domain of the type IX collagen alpha 1 chain from 17 day old chick embryos sterna as reported by Vasios et al. (J Biological Chem. 263, 2324-2329, 1998) on which the amino acid sequences identified from the MALDI-MS analysis of the polypeptides separated by 2D electrophoresis have been superimposed indicating where the sequences are identical as bold type and underlined.

20

Table 2: (SEQ ID NO. 1)

PRO-ARG-PHE-**PRO-VAL**-ASN-SER-ASN-SER-ASN / GLY-GLU-ASN-GLU-
LEU-CYS-PRO-LYS-VAL-**ARG / ILE-GLY-GLN-ASP-ASP-LEU-PRO-GLY-**
PHE-ASP / LEU-ILE-SER-GLN-PHE-GLN-ILE-ASP-LYS-ALA / ALA-SER-
ARG-ARG-ALA-ILE-GLN-ARG-VAL-VAL / GLY-SER-THR-ALA-LEU-GLN-
VAL-ALA-TRY-LYS / LEU-GLY-ASN-ASN-VAL-ASP-PHE-ARG / THR-ARG-

HIS-LEU-TYR-PRO-ASN-GLY-LEU-PRO / GLU-GLU-TYR-SER-PHE-LEU-THR-THR-PHE-ARG / MET-THR-GLY-SER-THR-LEU-GLY-LYS-HIS-TRP / SER-ILE-TRP-GLN-ILE-GLN-ASP-SER-SER-GLY / LYS-GLU-GLN-VAL-GLY-VAL-LYS-ILE-ASN-GLY / GLN-THR-LYS-SER-VAL-SER-PHE-SER-TRY-LYS / GLY-LEU-ASP-GLY-SER-LEU-GLN-THR-ALA-ALA / PHE-SER-ASN-LEU-PRO-SER-LEU-PHE-ASP-SER / GLN-TRP-HIS-LYS-ILE-MET-ILE-GLY-VAL-GLU / ARG-SER-SER-ALA-THR-LEU-PHE-VAL-ASP-CYS / ASN-ARG-ILE-GLU-SER-LEU-PRO-ILE-LYS-PRO

Table 3 below shows the human NC4 domain of the type IX collagen alpha 1 chain (sequences 24-268) obtained from the Swiss-Prot & TrEMBL data-bases (released 07-June-2004) on which the amino acid sequences identified from the MALDI-MS analysis of the polypeptides separated by 2D electrophoresis have been superimposed showing where the sequences are identical as bold type and underlined. Sequence 1-23 is the signal sequence for the human NC4 domain of the type IX collagen alpha 1 chain.

Table 3: (SEQ ID NO. 15)

1 Met Lys Thr Cys Trp Lys Ile Pro Val Phe Phe Phe Val Cys Ser 16 Phe Leu Glu Pro Trp Ala Ser Ala 23 Ala Val Lys Arg Arg **Pro Arg 31 Phe Pro Val Asn Ser Asn Ser Asn Gly Gly Asn Glu Leu Cys Pro 46 Lys Ile Arg Ile Gly Gln Asp Asp Leu Pro Gly Phe Asp Leu Ile 61 Ser Gln Phe Gln** Val **Asp Lys Ala Ala Ser Arg Arg Ala Ile Gln 76 Arg Val Val Gly Ser** Ala Thr **Leu Gln Val Ala Tyr Lys Leu Gly 91 Asn Asn Val Asp Phe Arg** Ile Pro Thr Arg Asn Leu Tyr Pro Ser 106 Gly Leu **Pro Glu Glu Tyr Ser Phe Leu Thr Thr Phe Arg Met Thr 121 Gly Ser Thr Leu Lys Lys Asn Trp Asn Ile Trp Gln Ile Gln Asp 136 Ser Ser Gly Lys Glu Gln Val Gly Ile Lys Ile Asn Gly Gln Thr 151 Gln Ser Val Val Phe Ser Tyr Lys Gly Leu Asp Gly Ser Leu Gln 166 Thr Ala Ala Phe Ser Asn Leu Ser Ser Leu Phe Asp Ser Gln Trp 181 His Lys Ile Met Ile Gly Val Glu Arg Ser Ser Ala Thr Leu Phe 196 Val Asp Cys Asn Arg Ile Glu Ser Leu Pro Ile Lys Pro** Arg Gly 211 Pro Ile Asp Ile Asp Gly Phe Ala Val Leu Gly Lys Leu Ala Asp 226 Asn Pro Gln Val Ser Val Pro Phe Glu Leu Gln Trp Met Leu Ile 241 His Cys Asp Pro Leu Arg Pro Arg Arg Glu Thr Cys His Glu Leu 256 Pro Ala Arg Ile Thr Pro Ser Gln Thr Thr Asp Glu Arg 268

By "substantially purified polypeptide" we mean a polypeptide that has been at least partially separated from the lipids, nucleic acids, other polypeptides, and other contaminating molecules with which it is associated in its native state. Preferably, the substantially purified polypeptide is at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other components with which they are naturally associated. Furthermore, the term "polypeptide" is used interchangeably herein with the term "protein".

The % identity of a polypeptide is determined by GAP (Needleman and Wunsch, 1970) analysis (GCG program) with a gap creation penalty=5, and a gap extension penalty=0.3. Unless stated otherwise, the query sequence is at least 15 amino acids in length, and the GAP analysis aligns the two sequences over a region of at least 15 amino acids. More preferably, the query sequence is at least 50 amino acids in length, and the GAP analysis aligns the two sequences over a region of at least 50 amino acids. Even more preferably, the query sequence is at least 100 amino acids in length and the GAP analysis aligns the two sequences over a region of at least 100 amino acids.

With regard to the defined polypeptides/enzymes, it will be appreciated that % identity figures higher than those provided above will encompass preferred embodiments. Thus, where applicable, in light of the minimum % identity figures, it is preferred that the polypeptide comprises an amino acid sequence which is at least 60%, more preferably at least 65%, more preferably at least 70%, more preferably at least 75%, more preferably at least 76%, more preferably at least 80%, more preferably at least 85%, more preferably at least 90%, more preferably at least 91%, more preferably at least 92%, more preferably at least 93%, more preferably at least 94%, more preferably at least 95%, more preferably at least 96%, more preferably at least 97%, more preferably at least 98%, more preferably at least 99%, more preferably at least 99.1%, more preferably at least 99.2%, more preferably at least 99.3%, more preferably at least 99.4%, more preferably at least 99.5%, more preferably at least 99.6%, more preferably at least 99.7%, more preferably at least 99.8%, and even more preferably at least 99.9% identical to the relevant nominated SEQ ID NO.

As used herein, the term "biologically active fragment" refers to a portion of the defined polypeptide which still maintains anti-arthritis or anti-inflammatory activity (whichever is relevant). Such biologically active fragments can readily be determined by serial deletions of the full length protein, and testing the activity of the resulting fragment.

Amino acid sequence mutants/variants of the polypeptides/enzymes defined herein can be prepared by introducing appropriate nucleotide changes into a nucleic

acid encoding the polypeptide, or by *in vitro* synthesis of the desired polypeptide. Such mutants include, for example, deletions, insertions or substitutions of residues within the amino acid sequence. A combination of deletion, insertion and substitution can be made to arrive at the final construct, provided that the final protein product possesses the desired characteristics.

In designing amino acid sequence mutants, the location of the mutation site and the nature of the mutation will depend on characteristic(s) to be modified. The sites for mutation can be modified individually or in series, e.g., by (1) substituting first with conservative amino acid choices and then with more radical selections depending upon the results achieved, (2) deleting the target residue, or (3) inserting other residues adjacent to the located site.

Amino acid sequence deletions generally range from about 1 to 30 residues, more preferably about 1 to 10 residues and typically about 1 to 5 contiguous residues.

Substitution mutants have at least one amino acid residue in the polypeptide molecule removed and a different residue inserted in its place. The sites of greatest interest for substitutional mutagenesis include sites identified as the active or binding site(s). Other sites of interest are those in which particular residues obtained from various strains or species are identical. These positions may be important for biological activity. These sites, especially those falling within a sequence of at least three other identically conserved sites, are preferably substituted in a relatively conservative manner. Such conservative substitutions are shown in Table 4.

Furthermore, if desired, unnatural amino acids or chemical amino acid analogues can be introduced as a substitution or addition into the polypeptides of the present invention. Such amino acids include, but are not limited to, the D-isomers of the common amino acids, 2,4-diaminobutyric acid, α -amino isobutyric acid, 4-aminobutyric acid, 2-aminobutyric acid, 6-amino hexanoic acid, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteine, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, β -alanine, fluoro-amino acids, designer amino acids such as β -methyl amino acids, C α -methyl amino acids, N α -methyl amino acids, and amino acid analogues in general.

TABLE 4. Exemplary substitutions.

Original Residue	Exemplary Substitutions
Ala (A)	val; leu; ile; gly
Arg (R)	lys
Asn (N)	gln; his
Asp (D)	glu
Cys (C)	ser
Gln (Q)	asn; his
Glu (E)	asp
Gly (G)	pro; ala
His (H)	asn; gln
Ile (I)	leu; val; ala
Leu (L)	ile; val; met; ala; phe
Lys (K)	arg
Met (M)	leu; phe
Phe (F)	leu; val; ala
Pro (P)	gly
Ser (S)	thr
Thr (T)	ser
Trp (W)	tyr
Tyr (Y)	trp; phe
Val (V)	ile; leu; met; phe; ala

- Also included within the scope of the invention are polypeptides of the present invention which are differentially modified during or after synthesis, e.g., by biotinylation, benzoylation, glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. These modifications may serve to increase the stability and/or bioactivity of the polypeptide of the invention.

- Polypeptides of the present invention can be produced in a variety of ways, including production and recovery of natural proteins, production and recovery of recombinant proteins, and chemical synthesis of the proteins. In one embodiment, an

isolated polypeptide of the present invention is produced by culturing a cell capable of expressing the polypeptide under conditions effective to produce the polypeptide, and recovering the polypeptide. A preferred cell to culture is a recombinant cell of the present invention. Effective culture conditions include, but are not limited to, effective media, bioreactor, temperature, pH and oxygen conditions that permit protein production. An effective medium refers to any medium in which a cell is cultured to produce a polypeptide of the present invention. Such medium typically comprises an aqueous medium having assimilable carbon, nitrogen and phosphate sources, and appropriate salts, minerals, metals and other nutrients, such as vitamins. Cells of the present invention can be cultured in conventional fermentation bioreactors, shake flasks, test tubes, microtiter dishes, and petri plates. Culturing can be carried out at a temperature, pH and oxygen content appropriate for a recombinant cell. Such culturing conditions are within the expertise of one of ordinary skill in the art.

15 **4. Preparation and administration of pharmaceutical compositions**

Compositions of the invention may be prepared from one or more polypeptide. Additional polypeptide fragments or peptides can be identified by routine experimentation in light of the present specification and figures. A method for identifying peptide fragments having stimulatory activity is described, for example, in US5,399,342.

The pharmaceutical compositions may be for human or animal usage in human and veterinary medicine and will typically comprise any one or more of a pharmaceutically acceptable diluent, carrier or excipient. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described for example in *Remington's Pharmaceutical Sciences* Mack Publishing Co. (A.R. Gennaro edit. 1985). The choice of pharmaceutical carrier excipient or diluent can be selected with regard to the intended route of administration and standard pharmaceutical practice. The pharmaceutical compositions may comprise as, or in addition to, the carrier, excipient or diluent, any suitable binder, lubricant, suspending agent, coating agent, or solubilizing agent.

It is well known in the art that there may be different composition/ formulation requirements dependant on the different delivery systems.

According to the present invention non-invasive formulations are particularly preferred. Where appropriate, the pharmaceutical compositions can be administered by inhalation, orally or intranasally, in the form of suppository or pessary, topically in the form of a lotion, solution, cream, ointment, or dusting powder, by use of a skin patch,

orally in the form of tablets containing excipients such as starch or lactose, or in capsules, chewables or ovules either alone or in admixture with excipients, or in the form of elixirs, solutions, syrups or suspensions containing flavouring or colouring agents.

- 5 For buccal or sublingual administrations, the compositions may be administered for example in the form of tablets or lozenges which can be formulated in a conventional manner.

Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium
10 saccharine, cellulose, magnesium carbonate, and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 10% to 95% of active ingredient, preferably 25% to 70%.

Capsules, tablets and pills for oral administration to a patient may be provided with an enteric coating comprising, for example, Eudragit "S", Eudragit "L", cellulose
15 acetate, cellulose acetate phthalate or hydroxypropylmethyl cellulose.

Intranasal formulations are described and administration of lathyrtyc collagen type II and lathyrtyc collagen type IX are described for example in Lu *et al* (1999) Different therapeutic and bystander effects by intranasal administration of homologous type II and type IX collagens on the collagen-induced arthritis and pristane-induced
20 arthritis in rats, *Clinical Immunology* Vol 90 pp 119-127 (1999).

In another example, the pharmaceutical composition of the present invention may be formulated to be delivered using a mini-pump or by a mucosal route, for example, as a nasal spray or aerosol for inhalation or ingestible solution.

Where the agent is to be delivered mucosally through the gastro-intestinal
25 mucosa, it should be able to remain stable during transit through the gastro-intestinal tract; for example, it should be resistant to proteolytic degradation, stable antacid, pH and resistant to the detergent effects of bile.

Preferably, the compositions of the invention are administered by a non-invasive route. Preferably, the non-invasive route comprises oral administration, or enteral
30 administration, nasal administration or by inhalation.

In an alternate embodiment, compositions of the invention can be injected parenterally for example, intravenously, intramuscularly or subcutaneously.

For parenteral administration, the compositions may be best used in the form of a sterile aqueous solution which may contain other substances, for example enough salts
35 or monosaccharides to make the solution isotonic with blood. The preparation may also be emulsified, or encapsulated in liposomes.

After formulation, the immuno-protective composition may be incorporated into a sterile container which is then sealed and stored at a low temperature, for example 4°C, or it may be freeze-dried. Lyophilisation permits long-term storage in a stabilised form.

5

5. *Treatment and protection of an individual*

The effects observed for the polypeptides on inflammation and collagen induced arthritis in rats also provide application for the polypeptides, and mixtures thereof, in the treatment, and protection of an individual to arthritis and other degenerative diseases. Further the effects observed provide application of the polypeptides in the tolerisation of an individual to the antigenic effects of cartilage components. Further, the finding provide application to methods of restoration of connective tissues, particularly in inflammatory and degenerative tissue diseases such as rheumatoid arthritis and osteoarthritis.

Polypeptides according to the invention that have been shown to have anti-inflammatory and/or anti-arthritic activity can be further tested for safety and efficacy in other animal models, and then proceed to clinical trials in humans, if desired. Naturally, for veterinary applications, no clinical trial in humans is required. Those polypeptides that are safe and efficacious in animals or humans can be administered to an appropriate subject to treat a connective tissue disease, or alternatively to protect against connective tissue disease by the process of tolerisation.

Rodent models of connective tissue disease are well known. For example, rat models for collagen induced arthritis and pristane induced arthritis rats are described in Lu *et al* (1999) (*supra*). Murine collagen induced models of arthritis are also described in Myers *et al* (2002) (*supra*).

Methods and pharmaceutical formulations for the treatment of autoimmune arthritis and animal models in mammals, including humans, by the oral, enteral or by-inhalation administration of whole collagen type II protein or biologically active peptide fragments of collagen type II are described in US 5,399,347 (Trentham *et al*). Further, methods and formulations for evaluating the efficacy of oral type II collagen in the treatment of juvenile rheumatoid arthritis (JRA) are described in Barnett *et al* (1996) (*supra*).

Intranasal formulations are described and administration of lathritic collagen type II and lathritic collagen type IX are described in Lu *et al* (1999) (*supra*).

The present invention provides methods of treatment of arthritis or other degenerative disease in animals, preferably mammals and more preferably humans.

"Treatment and protection" includes both prophylactic and therapeutic measures to prevent the onset and appearance of a connective tissue disease as well as to prevent the onset and appearance of an abnormal immune response against the body's own tissues involved in autoimmune disease. The term also encompasses the suppression or mitigation of the abnormal (cell and/or humoral) immune response to the body's own collagen or more generally cartilage as well as the alleviation or elimination of clinical symptoms after the onset (ie. clinical manifestation) of autoimmune disease.

"Autoimmune disease" is defined as a malfunction of the immune system of mammals, in which the immune system fails to distinguish between foreign substances within the mammal and/or autologous tissues or substances and, as a result, treats autologous tissues and substances as if they were foreign and mounts an immune response against them.

Tolerance

The present invention provides methods for inducing tolerance in an individual to at least one antigenic component of cartilage.

As used herein "tolerance" refers to the active state of specific immunologic nonresponsiveness induced by prior exposure to an antigen. Experimentally induced tolerance may be defined as a state in which an animal will fail to respond to an antigen that will normally be immunogenic. Immunologic tolerance does not simply reflect the absence of an immune response, but rather an active response of the immune system that exhibits antigenic specificity and memory - the hallmarks of any immune response. In experimentally induced tolerance a foreign antigen is administered under certain conditions that promotes a state of tolerance rather than immune activation. Antigen structure, dosage and route of administration each partly determine whether the response of the immune system will lead to immunity or tolerance. Experimental evidence demonstrating the role of these factors is provided in J. Kuby in *Immunology*, 2nd ed, WH Freeman and Company, 1994, Chapter 16.

As used herein the terms "immunotherapy" and "tolerance therapy" refer to any general method resulting in tolerance or immunological prophylaxis. In vivo, these therapies typically entail a series of parenteral or oral administrations of the immunogenic material over an extended period of time. In one embodiment, "tolerance therapy" refers to a method for the down-regulation of an immune response, eg., to suppress an inflammatory response to an auto-antigen.

Oral administration of antigens is an effective method of inducing peripheral T-cell tolerance. This phenomenon, often referred to as oral tolerance, has been well

studied in various models of autoimmune diseases in animals including encephalomyelitis, uveitis, diabetes, myasthenia gravis, and arthritis. The mechanisms for inducing tolerance, however, are not completely understood. All of the known mechanisms for tolerance induction, including clonal anergy, clonal deletion, and regulation by IL-4, IL-10, or TGF-beta-mediated active suppression may have a role in oral tolerance. Generally, higher doses of antigen are reported to induce anergy or clonal deletion whereas low doses induce cytokine regulation and active suppression.

Active suppression describes the regulation of one lymphocyte subset by another in an antigen-specific manner. Depending on the antigen and disease state, the suppressor cells may be CD4+ and/or CD8+ T-lymphocytes which migrate from peripheral lymphoid tissues, such as spleen and peripheral lymph nodes, to sites of disease activity. Adoptive transfer of these cells to naive recipients has confirmed the role of these cells in active suppression in rodent models of ovalbumin-induced hypersensitivity, and multiple sclerosis. *In vitro* evidence of active suppression is demonstrated by data showing that tolerized lymphocytes from animals can suppress proliferation of other antigen-specific T-lymphocytes across a transwell cell culture system (Faria and Weiner, "Oral tolerance: mechanisms and therapeutic applications," *Adv. Immunol.*, 73:153-264, 1999).

Clonal anergy refers to unresponsiveness of antigen-specific T-lymphocytes, which is characterized by diminished proliferation after exposure to an antigen, and is involved in oral tolerance in several animal models. Anergy could be the result of production of soluble suppressive factors by CD4+ or CD8+ T-lymphocytes themselves, other T-lymphocytes or cells in the local environment, or as result of decreased expression of appropriate costimulatory molecules. Clonal deletion refers to the elimination of antigen-specific T-lymphocytes, but has been reported rarely as a mechanism of oral tolerance to an antigen (Chen, Inobe, Marks, Gonnella, Kuchroo, Weiner, "Peripheral deletion of antigen-reactive T cells in oral tolerance," *Nature*, 376:177-180, 1995).

The soluble mediators that suppress the immune response during oral tolerance are derived mainly from regulatory or suppressor T-lymphocytes (Faria and Weiner 1999, *supra*). There are four types of T-lymphocytes described by the cytokines they produce: Th1-type that produce interleukin-2 (IL-2) and gamma interferon (K FN); Th2-type that produce IL-4 and IL-10; Th3-type that produce high levels of transforming growth factor beta (TGF- β), alone, or in conjunction with very low levels of IL-4, IL-10, or K.IFN; and Tr1 cells that produce high levels of IL-10 in conjunction with low levels of TGF- β . Since Th3, Th2, and Tr1-T-lymphocytes have been shown

to be the major mediators of active suppression induced by oral tolerance, then TGF-9, IL-4 and IL-10 are believed to be key cytokines in this process. Further reports showing that oral tolerance induction occurred in the absence of these cytokines suggests that other mediators or cells could suppress the immune response.

5 Studies of tolerance have focused primarily on the effect of the tolerizing antigen on T-lymphocyte function, and the role of T-lymphocytes in suppressing immune activation. However, immune responses to any antigen require interactions between APC's and T-lymphocytes, and the T-lymphocyte may affect APC function. Therefore, down-regulated antigen presentation by APC's from tolerized hosts could also
10 contribute to tolerance induction either indirectly as a result of interactions with suppressor T-lymphocytes, or possibly as a result of direct effects of the tolerizing antigen on the APC.

As used herein "degenerative disease", "degenerative condition" or "degenerative disorder" are used interchangeably to refer to conditions that are characterised by a
15 breakdown of a biological tissue, more particularly a connective tissue. Connective tissue refers to those animal tissue that supports organs, fills spaces between them, or performs mechanical functions such as connecting muscles to bone (tendons and ligaments) or providing low friction weighing surface as in articular cartilage. Connective tissues are characterized by their relatively avascular matrices and low cell
20 densities. The most abundant connective tissues are the reticular stroma, muscle, adipose tissue, cartilage and bone.

The term "tissue" as used herein refers to matrices which contain similarly specialised cells that perform a common function. As used herein, tissue is intended to include an organ composed of a given tissue, and to the cells individually or collectively
25 that compose the tissue.

As used herein "autoimmune disease" refers to a disease characterised by a humoral (eg., antibody-mediated), cellular (eg., cytotoxic T-lymphocyte-mediated), or a combination of both types of immune responses to epitopes on self-antigens. The immune system of the affected individual activates inflammatory cascades aimed at
30 cells and tissues presenting those specific-self antigens. The destruction of the antigen, tissue, cell type or organ attacked gives rise to further symptoms of the disease. In a preferred embodiment of the invention the disease is selected from the group consisting of rheumatoid arthritis, osteoarthritis, disc degeneration and osteoporosis.

The terms self-antigens or auto-antigens are used interchangeably to refer to an
35 antigen that is endogenous to an individual's physiology, that is recognised by either the

cellular component (eg T-cell or B-cell receptors) or humeral component (antibodies) of that individual's system.

MODES FOR CARRYING OUT THE INVENTION

1. Experimental Protocols

Bovine, ovine, cervine or porcine tracheal cartilage or nasal cartilage, chicken sternal cartilage, or skeletal shark cartilage or deer antler cartilage were freed of adhering soft tissues mechanically or as described previously US Patent 5,399,347 Mar 1995, US Patent 5,364,845 Dec 1996, US Patent 6,025,327 Feb 2000). These cleaned
 10 hyaline cartilages were rinsed with water, minced into 1 mm or 3 mm sizes, freeze dried and stored at -20 °C. Bovine tracheal chondroitin sulfate A (ChSA) was purchased from Sigma Chemical Co, USA or was obtained as a gift from Bioiberica, Barcelona, Spain (batch 1/0015, batch 05/2001, batch 18/11/99). All other chemicals were of analytical grade and were purchased from local suppliers.

15

Release of Glycosaminoglycan Peptide (GAG-peptide) Complexes and polypeptides from the Cartilage Powders

Studies on the kinetics of release of the GAG-peptides and polypeptides from the cartilage powders were performed using different buffers (eg sodium or calcium acetate
 20 or dilute acetic acid) to give various products referred to herein as "Peptacan(s)" and was undertaken under a variety of conditions. The objective of these experiments was to determine the effects of (i) particle size - 3mm,5mm, (ii) different pHs eg. pH range 3.5-7.0, (iii) different temperatures, 4°C, 25°C and 37°C, and (iv) animal species and tissue locations on the rate of autolysis and product release into the aqueous phase. All
 25 the experiments were performed, with stirring and release of sulphated GAGs and polypeptides monitored over 24 hours. In the initial studies undertaken, the primary observation was that subjecting particles of cartilages to autolysis in aqueous buffers maintained within the pH range of 4.0-7.0, particularly 4.5, preferably at 37°C for periods up to 24 hours specifically released more than 80% of the total sulfated
 30 glycosaminoglycans (S-GAG) into solution. Studies also showed that the rate of release was dependent on the cartilage particle size, the smaller preparations undergoing more rapid release. However, by 24 hours the yields obtained were the same. The pH and temperature were found to be important determinants of the rate of release which indicated that the release process was mediated by endogenous enzymes present within
 35 the solid tissues. This proposed mechanism was confirmed by undertaking autolysis experiments in the absence and presence of specific enzyme inhibitors. Since it was

found that the addition of N-ethylmaleimide produced the most significant inhibition of GAG-peptide and polypeptides release into the aqueous medium we consider that the cysteine class of proteinases, such as the Cathepsins, were the major, but not exclusive, contributors to the autolytic process.

5 The aqueous phase was separated from the cartilage powders by filtration and the filtrate centrifuged to remove fine particles and then neutralised to pH 7.0 by addition of an alkaline solution containing the desired cation. These Peptacan solutions after chemical analysis were either freeze dried and used directly for pharmacological studies. The freeze dried Peptacans were used as stock material for the preparation of
10 dialysed and fractionated preparations as described below.

 Alternatively the Peptacans could be isolated from the aqueous solutions obtained from the cartilage digests by precipitation with excess quantities of acetone, ethanol or methanol, usually by adding 3-5X the volume of the aqueous extracts. The precipitates so obtained would be washed with absolute ethanol and dried under vacuum
15 then stored in a vacuum desiccator.

 The process of the present invention is essentially non-disruptive leaving the type II collagen matrix and cells of the tissue intact, and the absence of DNA in the autolysis media. The efficiency of the autolytic process was also influenced by the animal species and anatomical location from where the cartilage was derived as well as
20 the nature of the buffers used.

 For the further experiments described herein, the results were obtained following subjecting bovine tracheal cartilage to autolysis with calcium acetate buffer. For the purpose of convenience, the product obtained by this process is referred to herein as Calcium Peptacan (CaP).
25

Separation of Glycosaminoglycan Peptides (GAG-peptides) from polypeptides in Peptacan preparations by Ion-exchange solid phase media (see schema shown in Figure 2)

 Freeze-dried Peptacans was dissolved in 0.1M calcium chloride buffered with
30 Tris-HCl to a pH of 7.2 (application buffer) to afford sample concentrations of 4.0 mg/ml. To these solutions was added pre-swollen DEAE-Sepharose-6B to achieve a final concentration of the ion exchanger of 100mg/mL. This mixture was maintained at room temperature with gentle agitation for 16 hours in 5mL stoppered centrifuge tubes. The tubes were then centrifuged at 1000rpm for 5 mins and the supernatant decanted
35 off. To the remaining pellet was added 1mL of the application buffer and the tubes gently shaken, centrifuged again and the application buffer washings added to the

original supernatant. The supernatant and washings contains the proteins and polypeptides in the Peptacan preparations.

Fractionation of the Peptacan proteins and polypeptides

5 The supernatant and washings from the ion exchange process were subjected to diafiltration using a 1000Da cut-off ultrafiltration membrane (eg, YC10) or a tangential flow ultrafiltration (TFF) cartridge of similar cut-off (Millipore Australia Pty Ltd, Sydney, Australia), to remove the inorganic ions. The diafiltrated de-salted polypeptide solution was then freeze-dried and stored at -20°C . Subjecting aqueous solutions of

10 these polypeptides to further fractionation using TFF membranes of different molecular weight cut-offs afforded polypeptides of predetermined molecular size. For example using a PLTC regenerated cellulose membrane with an exclusion size of 30,000 (Millipore Australia Pty Ltd, Sydney, Australia) afforded a mixture of polypeptides in the retentate with molecular weights greater than 30,000Da. These proteins and

15 polypeptides were freeze dried and assigned the code of INR-307 for subsequent experiments. The dialysate from the first TFF contained polypeptides with molecular weights less than 30,000Da but greater than 1,000Da. This fraction was designated the code INR-126 for subsequent experiments. In addition the dialysate from the 30,000Da TFF step was also subject to TFF using a polyethersulfone spiral cartridge (Millipore

20 Australia Pty Ltd, Sydney, Australia) with an exclusion size of 10,000 Da which provided a retentate containing polypeptides with molecular weights $> 10,000$ Da. These polypeptides were assigned the code INR-195 for subsequent experiments. The efficiency of the separations of these polypeptides into the molecular ranges cited was confirmed by SDS-PAGE using proteins of known molecular weight as standards such

25 as those shown in Figures 3 and 4.

Further fractionation of the polypeptide solutions can be achieved using any one or combination of techniques such as, for example, gel filtration, ultrafiltration, SDS PAGE electrophoresis, 2D gel electrophoresis, and reverse phase HPLC using established methods (see for example, Eyre D, et al. Collagen type IX: evidence for

30 covalent linkages to type II collagen in cartilage. FEB 220:337-341,1987).

Detailed preparation of INR-195

In this procedure the supernatant and washings containing the polypeptide components obtained from ion exchange separation of calcium peptacan using DEAE-Sephacrose were transferred to a reservoir connected via a peristaltic pump to a 10kD

35 PLAC (PL series Cellulose or polysulfone 0.93 square metre spiral cartridge (Millipore

Australia Pty Ltd). The peptide containing solution is then subjected to tangential flow filtration for 6 hours by addition of purified water to the reservoir to dialysis off the small inorganic ions used for ion exchange procedure as well as peptides with molecular weights below the cut-off of the membrane. The retentate was then concentrated by diafiltration in the same apparatus, collected and water removed by freeze drying. In such a procedure the product obtained by this method was designated as INR-195 and was used for the rat CIA experiments described herein.

2. BIOLOGICAL ACTIVITY

10 *Determination of collagen or collagen peptide content in preparations by assay for hydroxyproline*

The collagen content of polypeptides separated by ion exchange was estimated by measuring the concentration of the amino acid hydroxyproline which is unique to this protein. Each freeze dried sample was directly dissolved in H₂O (10 mg/ml) and then hydrolysed in 5 N HCl at 110 °C for 24 h. The hydrolysed sample solution was neutralised to pH 7 before dilution and analysis. The hydroxyproline concentration in these solutions was determined using the method of Stegman and Stalder (Stegman H and Stalder K. Determination of Hydroxyproline. Clin. Chim. Acta 18:267-273, 1967) by using a L-hydroxyproline standard and measuring the absorbance at 562 nm after the addition of chloramine T and p-dimethylaminobenzaldehyde to develop the chromophore. The hydroxyproline concentration was multiplied by 7.4 to give an estimate of the collagen content.

Determination of Protein content of preparations content by the Bicinchoninic Acid (BCA) assay

- The total protein content of polypeptide samples was determined using BCA assay (Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ and Klenk DC. Anal. Biochem. 150, 76–85, 1985). Freeze dried polypeptide samples were directly dissolved in H₂O to provide a 2.0 mg/ml solution and 20 µl of each sample solution was added to a well of 96-well plates. Just prior to assay, 50 parts of reagent 1 (0.4% NaOH; 1.7% Na₂CO₃; 0.95% NaHCO₃; 1.0% bicinchoninic acid; 0.16% Na₂-tartrate) was mixed with reagent 2 (4% CuSO₄.5H₂O).
- Two hundred micro litres of this working reagent was added to the sample solution. After incubation at 37°C for 60 min the absorbance A₅₆₂ was read using a Thermomax microplate reader. Bovine serum albumin (BSA) or highly purified gelatine (Gibco) at 0–10 µg/well were used to construct a standard curve.

Analysis of polypeptides separated by ion exchange using SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE)

- Freeze dried polypeptide samples were dissolved in H₂O and then mixed 1:1 with 2x sample loading buffer (0.07 M TrisHCl, 1.5% SDS, 20% glycerol, 0.2M DTT and 0.1% BPB) to achieve the final concentrations of 4.0 – 20 mg/ml. The samples were boiled in a water bath for 5 min. 20 µl of above samples were loaded into the wells of 8 – 16 % pre-cast Tris-glycine gel (Norvex). SeeBlue pre-stained low molecular weight range protein markers (Norvex) were loaded into wells on the left-hand side of the gel and electrophoresis was performed at 125 V for 2 h. The gel was stained in Coomassie blue R250 solution (40% ethanol, 10% acetic acid and 0.2% Coomassie R250) for 30 min and destained in a solution containing 10% ethanol and 7.5% acetic acid for 16 h. The gel was dried in a Bio-Rad Gelair drier.

- SDS-PAGE of the polypeptides separated from the GAG-peptides by the ion exchange procedure showed the presence of a number of bands the most abundant of which had molecular weights of 36kDaltons or less (Figure 2).

30

Analysis of polypeptides separated by ion exchange using two-Dimensional gradient SDS-PAGE

- Freeze dried polypeptide samples (6.5mg) were dissolved in H₂O and sonicated. Samples were then centrifuged at 20,000g for 10 minutes then were loaded via in-gel rehydration methods for Isoelectric Focusing (IEF) using 11 cm gradient strips over a pH of 3–10. First Dimension focusing was at 35,000Vh. The second dimension used

separating gradient 8-18%T criterion format polyacrylamide slab gels. This second dimension electrophoresis was run at 1 hour @ 5mA/gel and 4 hours @ 15mA/gel. Gels were stained using SYPRO Ruby fluorescent stain then scanned to produce a digital image.

- 5 Two dimensional electrophoresis of the polypeptides separated from the GAG-peptides by the ion exchange procedure revealed the presence of at least 21 polypeptides (Figure 4).

10 *Tryptic digestion and Matrix assisted laser desorption ionisation (MALDI) mass spectrometry*

- Following two-dimensional gradient SDS-PAGE of samples they were subjected to an in gel 16 hour tryptic digest at 37°C. The resulting peptides were extracted from the gel with a 10% (v/v) acetonitrile, 1% (v/v) TFA solution. The samples were then cleaned up and concentrated using ZipTip. A 1µL aliquot of each was spotted onto a sample plate with 1µL of matrix (a-cyano-4-hydroxycinnamic acid, 8mg/mL in 70% v/v AcN, 1% v/v TFA) and allowed to air dry. Matrix assisted laser desorption ionisation (MALDI) mass spectrometry was then performed with a Micromass Maldi Time of Flight Mass Spectrometer. A nitrogen laser (337 nm) was used to irradiate the sample. The spectra were acquired in reflectron mode in the mass range 750 to 3500 Da. A near point calibration was applied.

The peptide masses of the monoisotopic peak of the peptides from this analysis were searched against Bovine using ProteinLynx on MassLynx and Mammalia data bases using PeptIdent on ExPASy.

25 *Rat collagen induced arthritis (CIA)*

- Two protocols, which are summarized in Figure 5, were used to evaluate the anti-arthritis activities of the polypeptides isolated in this invention. The toleragenic protocol required that the polypeptides dissolved in water were given orally each day to Female Wistar rats (160-180 gm) 7 days before inducing the arthritis by the inoculation with 250 µg bovine tracheal type II collagen, given as 6 divided injections into their tailbase. In the therapeutic/prophylactic protocol the polypeptides were administered orally on the same day as the arthritis was induced in the animals and everyday thereafter.

- 35 The following signs of arthritis were assessed from Day 11 onwards but recorded for each experimental group on days 15 and 18 (see Tables 5 and 6 below).

Table 5 shows the results obtained for the anti-arthritis effects of the polypeptide fractions INR-126, INR-195 and the established anti-rheumatoid arthritis drug, aurothiomalate (ATM) using the rat CIA-prophylactic/therapeutic protocol. Note that INR-126 and INR-195 appear to show similar anti-arthritis activities at 20 mg/kg and are both superior to ATM in this animal model.

Table 5:

Results demonstrating anti-arthritis activity of the polypeptides INR-195 and INR-126 relative to ATM in the Rat CIA model using the Prophylactic/Therapeutic protocol(15 days treatment)

Rx n=4	Dose mg/kg	Mean arthritis scores			Signs of arthritis Day 15			Signs of arthritis Day 18		
		Day 13	Day 15	Day 18	R/paw swell (mm)	F/paw swell (mm)	Weight change (g)	R/paw swell (mm)	F/paw swell (mm)	Weight change (g)
None	—	0.7	1.5	1.8	0.7	2.1	+40	0.8	2.0	-04
INR-126	20 (oral)	0.2**	0.8*	1.3	0.4	1.3*	+47	0.7	2.0	+06
INR-126	200 (oral)	0.2**	0.5*	1.7	0.1	0.1**	+58	0.8	2.3	+04
INR-195	20 (oral)	0.2*	0.7*	1.8	0.2	0.1**	+45	0.7	2.0	+09
ATM	6.3 (SC)	0.8	2.1	2.1	0.7	2.5	+47	0.8	3.2	+04

ATM = Aurothiomalate, SC = subcutaneously, ** = $p < 0.005$ * = $p < 0.05$ relative to none

Table 6 shows the results obtained for the anti-arthritis effects of the polypeptide fractions INR-126, INR-195 using the rat CIA-toleragenic protocol. Note that the smaller MW fraction INR-126 appears to exhibit a more longer lasting toleragenic activity than the higher MW fraction, INR-195.

Table 6:

Results demonstrating the anti-arthritis activity of the polypeptides INR-195 and INR-126 in the Rat CIA model using the toleragenic protocol where preparations are given for 7 days before inducing arthritis

Rx n=4	Dose mg/kg	Mean arthritis scores			Signs of arthritis Day 15			Signs of arthritis Day 18		
		Day 13	Day 15	Day 18	R/paw swell (mm)	F/paw swell (mm)	Weight change (g)	R/paw swell (mm)	F/paw swell (mm)	Weight change (g)
None	—	0.7	1.3	1.5	0.8	2.8	+58	0.8	2.5	-01
INR-126	20 (oral)	0.1**	0.6*	0.5**	0.2*	1.4*	+50	0.06**	1.1*	+09
INR-195	20 (oral)	0.6	0.5*	1.5	0.1*	0.1*	+44	0.6	1.5	+05

** = $p < 0.005$ * = $p < 0.05$ relative to no treatment group

5

- Rear paw swelling, fore paw swelling (measured as the change in mm relative to non-arthritic controls) and an overall arthritis score (scored 0-4+) determined on the basis of overall inflammation and other signs of disease e.g. piloerection, diminished mobility, poor grooming etc were determined as described previously (Lu S *et al*, Different therapeutic and bystander effects by intranasal administration of homologous type II and type IX collagens on the collagen- induced arthritis and Pristane-induced arthritis in rats. Clin Immunol. 90:119-127, 1999).

15 Preparations of stained histological sections of rat joints.

- Following sacrifice of the experimental animals rear and front paw joints were removed surgically and immediately placed in neutral buffered formaldehyde and processed for preparation of H and E and toluidine blue stained histological sections as described previously (Smith MM, Numata Y and Ghosh P, Effects of calcium pentosan polysulfate on joint inflammation and pouch fluid levels of leukocytes, nitric oxide and interleukin-6 in a rat model of arthritis. Current Therapeutic Research, 60: 561-576, 1999).

3. DISCUSSION

Positive identification of 17 of the polypeptides took account of the percentage of sequence coverage, how well the masses matched the significant peaks in the MS spectra, the number of missed cleavages (if missed cleavages were present their location in the sequence was critical) and how well the MW and pI of the identified protein match. These sequences and their % match with known proteins are shown in Table 7 below.

Table 7 identifies the polypeptides separated by the SDS-PAGE 2-D electrophoresis after tryptic digestion and MALDI-MS of the cleaved fragments determined by comparison with corresponding trypsin digestion fragments available in published databases.

Table 7:

1
Tentative
NCF1_BOVIN
Neutrophil cytosol factor 1
Molecular weight: 45346
Matches: 5
MOWSE Score: 1.6076937e+003
Likelihood: 1.96e+003
Coverage: 14.80 %
Matching peptides:
MW Delta Start End Sequence
841.4657 -88.56 120 126 (K)VRPDD LK(L)
886.4760 -21.99 127 134 (K)LPTDS QVK(K)
886.4508 -50.37 283 291 (K)AGQDV AQAK(S)
* 1164.5822 0.02 328 336 (R)NSVRF MQQR(R)
1730.7934 -0.01 56 70 (K)EMFPI EAGDI NPENR(I)
1891.9197 23.26 170 188 (K)GSSSQ MALAT GDVVD VVEK(N)
OR
Tentative
ALBU_BOVIN
Bovine Serum Albumin
Molecular weight: 69294
Matches: 5
MOWSE Score: 7.6716406e+001

<p>Likelihood: 1.88e+003</p> <p>Coverage: 8.73 %</p> <p>Matching peptides:</p> <p>MW Delta Start End Sequence</p> <p>711.3664 59.75 29 34 (K)SEIAH R(F)</p> <p>* 959.5400 -35.02 210 218 (R)EKVLA SSAR(Q)</p> <p>* 1000.5818 -23.99 233 241 (R)ALKAW SVAR(L)</p> <p>1385.6133 -28.71 286 297 (K)YICDN QDTIS SK(L)</p> <p>* 1961.9404 26.67 139 155 (K)LKPDP NTLCD EFKAD EK(K)</p>
<p>2</p> <p>Tentative</p> <p>Score: 0.19, 6 matching peptides: P35445 (COMP_BOVIN) pI: undefined, Mw: undefined</p> <p>Cartilage oligomeric matrix protein (COMP) (Fragment). - Bos taurus (Bovine).</p> <p>user mass matching [Delta] #MC modification positionpeptide</p> <p>mass (ppm) mass</p> <p>887.4908 887.4404 -56.88 0 Cys_PAM: 10 8-14 DNCPLVR</p> <p>1181.5063 1181.4463 -50.84 0 2xCys_PAM 26-34 WGDACDNCR</p> <p>1226.6927 1226.631 -50.35 1 Cys_PAM: 69 62-71 IRNPVDNCPK</p> <p>1337.5306 1337.491 -29.64 0 Cys_PAM: 53 50-61 GDACDDIDGDR</p> <p>1370.707 1370.6369 -51.19 0 168-179 LVPNPGQEDMDR</p> <p>1386.6544 1386.6318 -16.32 0 MSO: 177 168-179 LVPNPGQEDMDR</p> <p>11.4% of sequence covered:</p>
<p>3</p> <p>No Good Match</p>
<p>4</p> <p>No Good Match</p>
<p>5</p> <p>No Good Match</p>
<p>6</p> <p>No Good Match</p>
<p>7</p> <p>ALBU_BOVIN</p>

Bovine Serum Albumin**Molecular weight: 69294**

Matches: 11

MOWSE Score: 9.5664269e+006

Likelihood: 4.27e+003

Coverage: 17.96 %

Matching peptides:

MW Delta Start End Sequence

926.4862 -137.94 161 167 (K)YLYEI AR(R)

1162.6234 -74.58 66 75 (K)LVNEL TEFAK(T)

1282.7033 -96.76 361 371 (R)HPEYA VSVLL R(L)

1304.7088 -90.40 402 412 (K)HLVDE PQNLI K(Q)

* 1438.8045 -82.02 360 371 (R)RHPEY AVSVL LR(L)

1478.7881 -92.19 421 433 (K)LGEYG FQNAL IVR(Y)

1510.8355 -83.71 438 451 (K)VPQVS TPTLV EVSR(S)

1566.7354 -87.40 347 359 (K)DAFLG SFLYE YSR(R)

* 1638.9304 -66.09 437 451 (R)KVPQV STPTL VEVSR(S)

1414.6802 -38.28 569 580 (K)TVMEN FVAFV DK(C)

+ Methionine Sulfoxide

1893.9294 -61.74 508 523 (R)RPCFS ALTPD ETYVP K(A)

+ Cysteine acrylamide

8

ALBU_BOVIN

Bovine Serum Albumin**Molecular weight: 69294**

Matches: 13

MOWSE Score: 7.6034479e+007

Likelihood: 1.17e+004

Coverage: 21.42 %

Matching peptides:

MW Delta Start End Sequence

926.4862 -72.22 161 167 (K)YLYEI AR(R)

1162.6234 -28.39 66 75 (K)LVNEL TEFAK(T)

1282.7033 -47.50 361 371 (R)HPEYA VSVLL R(L)

1304.7088 -31.77 402 412 (K)HLVDE PQNLI K(Q)

* 1438.8045 -39.49 360 371 (R)RHPEY AVSVL LR(L)
 1478.7881 -32.08 421 433 (K)LGEYG FQNAL IVR(Y)
 1510.8355 -19.52 438 451 (K)VPQVS TPTLV EVSR(S)
 1518.7388 -25.79 139 151 (K)LKPD PNTLCD EFK(A)
 1566.7354 -34.55 347 359 (K)DAFLG SFLYE YSR(R)
 * 1638.9304 -19.36 437 451 (R)KVPQV STPTL VEVSR(S)
 * 988.5488 24.47 221 228 (R)LRCAS IQK(F)
 + Cysteine acrylamide
 1414.6802 8.58 569 580 (K)TVMEN FVAFV DK(C)
 + Methionine Sulfoxide
 1893.9294 -10.63 508 523 (R)RPCFS ALTPD ETYVP K(A)
 + Cysteine acrylamide

9

NCF1_BOVIN

10

Q95L50

Type IX collagen alpha 1 chain

Molecular weight: 20907

Matches: 5

MOWSE Score: 3.7725965e+003

Likelihood: 5.46e+003

Coverage: 28.34 %

Matching peptides:

MW Delta Start End Sequence

933.4668 -63.69 61 68 (K)LGNNV DFR(I)

1051.6390 -43.95 173 181 (R)IESLP IKPR(G)

2183.0687 42.58 73 90 (R)HLYPN GLPEE YSFLT TFR(M)

832.4476 -30.07 155 161 (K)IMIGV ER(S)

+ Methionine Sulfoxide

1282.5976 -22.54 162 172 (R)SSATL FVDCN R(I)

+ Cysteine acrylamide

11

ALBU_BOVIN

Bovine Serum Albumin

Molecular weight: 69294

Matches: 5

MOWSE Score: 1.1175735e+003

Likelihood: 7.26e+002

Coverage: 10.21 %

Matching peptides:

MW Delta Start End Sequence

926.4862 -156.39 161 167 (K)YLYEI AR(R)

1282.7033 -36.27 361 371 (R)HPEYA VSVLL R(L)

1566.7354 -84.65 347 359 (K)DAFLG SFLYE YSR(R)

* 1887.9876 -6.32 89 105 (K)SLHTL FGDEL CKVAS LR(E)

1887.9195 -42.39 169 183 (R)HPYFY APELL YYANK(Y)

1790.7021 -70.93 267 280 (K)ECCHG DLLEC ADDR(A)

+ Cysteine acrylamide

+ Cysteine acrylamide

+ Cysteine acrylamide

12

ALBU_BOVIN

Bovine Serum Albumin

Molecular weight: 69294

Matches: 16

MOWSE Score: 3.5119435e+010

Likelihood: 1.04e+004

Coverage: 28.17 %

Matching peptides:

MW Delta Start End Sequence

926.4862 -106.87 161 167 (K)YLYEI AR(R)

1282.7033 28.51 361 371 (R)HPEYA VSVLL R(L)

1304.7088 -33.76 402 412 (K)HLVDE PQNLI K(Q)

1478.7881 -58.18 421 433 (K)LGEYG FQNAL IVR(Y)

1510.8355 -34.08 438 451 (K)VPQVS TPTLV EVSR(S)

* 1638.9304 -30.89 437 451 (R)KVPQV STPTL VEVSR(S)

* 1737.8032 -39.00 387 401 (K)DDPHA CYSTV FDKLK(H)

1120.5223 -76.32 588 597 (K)EACFA VEGPK(L)

+ Cysteine acrylamide

1165.5220 -96.70 499 507 (K)CTES LVNR(R)

+ Cysteine acrylamide
 + Cysteine acrylamide
 1193.5169 -102.89 460 468 (R)CCTKP ESER(M)
 + Cysteine acrylamide
 + Cysteine acrylamide
 1414.6802 16.07 569 580 (K)TVMEN FVAFV DK(C)
 + Methionine Sulfoxide
 1567.6613 9.82 387 399 (K)DDPHA CYSTV FDK(L)
 + Cysteine acrylamide
 1589.7759 24.36 139 151 (K)LKPDN NTLCD EFK(A)
 + Cysteine acrylamide
 1753.8379 17.95 469 482 (R)MPCTE DYLSL ILNR(L)
 + Methionine Sulfoxide
 + Cysteine acrylamide
 1893.9294 -3.13 508 523 (R)RPCFS ALTPD ETYVP K(A)
 + Cysteine acrylamide
 1920.9291 10.74 529 544 (K)LFTH ADICT LPDTE K(Q)
 + Cysteine acrylamide

13

Q95L50

Type IX collagen alpha 1 chain

Molecular weight: 20907

Matches: 9

MOWSE Score: 1.6928014e+007

Likelihood: 1.54e+004

Coverage: 62.03 %

Matching peptides:

MW Delta Start End Sequence

816.4018 -95.42 124 130 (K)SVSFS YK(G)

816.4527 -32.98 155 161 (K)IMIGV ER(S)

933.4668 -51.91 61 68 (K)LGNNV DFR(I)

1051.6390 -49.75 173 181 (R)IESLP IKPR(G)

1570.7528 -9.01 99 111 (K)HWSIW QIQDS SGK(E)

2148.0739 -6.99 21 39 (R)IGQDD LPGFD LISQF QIDK(A)

2183.0687 -12.48 73 90 (R)HLYPN GLPEE YSFLT TFR(M)

2618.2765 -0.04 131 154 (K)GLDGS LQTAA FSNLP SLFDS QWHK(I)

832.4476 -3.52 155 161 (K)IMIGV ER(S)

+ Methionine Sulfoxide

1282.5976 -44.29 162 172 (R)SSATL FVDCN R(I)

+ Cysteine acrylamide

14

Q95L50

Type IX collagen alpha 1 chain

Molecular weight: 20907

Matches: 9

MOWSE Score: 1.6928014e+00

Likelihood: 8.48e+003

Coverage: 62.03 %

Matching peptides:

MW Delta Start End Sequence

816.4018 -156.04 124 130 (K)SVSFS YK(G)

816.4527 -93.60 155 161 (K)IMIGV ER(S)

933.4668 -138.67 61 68 (K)LGNNV DFR(I)

1051.6390 -126.57 173 181 (R)IESLP IKPR(G)

1570.7528 -78.20 99 111 (K)HWSIW QIQDS SGK(E)

2148.0739 -53.45 21 39 (R)IGQDD LPGFD LISQF QIDK(A)

2183.0687 -61.45 73 90 (R)HLYPN GLPEE YSFLT TFR(M)

2618.2765 -0.10 131 154 (K)GLDGS LQTAA FSNLP SLFDS QWHK(I)

832.4476 -105.98 155 161 (K)IMIGV ER(S)

+ Methionine Sulfoxide

1282.5976 -119.59 162 172 (R)SSATL FVDCN R(I)

+ Cysteine acrylamide

15

Q95L50

Type IX collagen alpha 1 chain

Molecular weight: 20907

Matches: 7

MOWSE Score: 5.0424749e+005

Likelihood: 8.67e+003

Coverage: 48.13 %

Matching peptides:

MW Delta Start End Sequence

816.4018 103.26 124 130 (K)SVSFS YK(G)

816.4527 165.71 155 161 (K)IMIGV ER(S)

933.4668 13.11 61 68 (K)LGNNV DFR(I)

1051.6390 5.50 173 181 (R)IESLP IKPR(G)

1570.7528 -0.05 99 111 (K)HWSIW QIQDS SGK(E)

2183.0687 -17.84 73 90 (R)HLYPN GLPEE YSFLT TFR(M)

2618.2765 0.11 131 154 (K)GLDGS LQTAA FSNLP SLFDS QWHK(I)

1282.5976 -29.95 162 172 (R)SSATL FVDCN R(I)

+ Cysteine acrylamide

16

Q95L50

Type IX collagen alpha 1 chain

Molecular weight: 20907

Matches: 5

MOWSE Score: 1.6468835e+004

Likelihood: 8.25e+003

Coverage: 34.76 %

Matching peptides:

MW Delta Start End Sequence

933.4668 35.82 61 68 (K)LGNNV DFR(I)

1051.6390 30.60 173 181 (R)IESLP IKPR(G)

2148.0739 0.08 21 39 (R)IGQDD LPGFD LISQF QIDK(A)

2183.0687 -1.95 73 90 (R)HLYPN GLPEE YSFLT TFR(M)

1282.5976 -7.80 162 172 (R)SSATL FVDCN R(I)

+ Cysteine acrylamide

17

Q95L50

Type IX collagen alpha 1 chain

Molecular weight: 20907

Matches: 8

MOWSE Score: 9.0085540e+005

Likelihood: 5.86e+003

Coverage: 49.20 %

Matching peptides:

MW Delta Start End Sequence

816.4018 -137.06 124 130 (K)SVSFS YK(G)

816.4527 -74.62 155 161 (K)IMIGV ER(S)

933.4668 -125.07 61 68 (K)LGNNV DFR(I)

1051.6390 -117.92 173 181 (R)IESLP IKPR(G)

1570.7528 -50.26 99 111 (K)HWSIW QIQDS SGK(E)

2148.0739 -4.71 21 39 (R)IGQDD LPGFD LISQF QIDK(A)

2183.0687 -24.99 73 90 (R)HLYPN GLPEE YSFLT TFR(M)

832.4476 -86.04 155 161 (K)IMIGV ER(S)

+ Methionine Sulfoxide

1282.5976 -97.22 162 172 (R)SSATL FVDCN R(I)

+ Cysteine acrylamide

18

Q95L50

Type IX collagen alpha 1 chain

Molecular weight: 20907

Matches: 5

MOWSE Score: 1.6468835e+004

Likelihood: 2.56e+003

Coverage: 34.76 %

Matching peptides:

MW Delta Start End Sequence

933.4668 -122.28 61 68 (K)LGNNV DFR(I)

1051.6390 -107.17 173 181 (R)IESLP IKPR(G)

2148.0739 0.02 21 39 (R)IGQDD LPGFD LISQF QIDK(A)

2183.0687 -6.21 73 90 (R)HLYPN GLPEE YSFLT TFR(M)

1282.5976 -90.21 162 172 (R)SSATL FVDCN R(I)

+ Cysteine acrylamide

19

OBP_BOVIN

Odorant-binding protein

Molecular weight: 18503

Matches: 7

MOWSE Score: 4.8550116e+005

Likelihood: 2.71e+004

Coverage: 50.94 %

Matching peptides:

MW Delta Start End Sequence

959.4825 -4.49 30 37 (K)IQENG PFR(T)

993.4655 32.50 42 49 (R)ELVFD DEK(G)

1161.5706 1.66 50 59 (K)GTVDF YFSVK(R)

1207.6085 18.62 19 29 (R)TVYIG STNPE K(I)

1359.7259 -11.18 97 108 (R)THLVA HNINV DK(H)

1788.8067 1.86 145 159 (K)NVVNF LENED HPHPE(-)

1947.8486 2.44 74 90 (K)QDDGT YVADY EGQNV FK(I)

20

Q95L50

Type IX collagen alpha 1 chain

Molecular weight: 20907

Matches: 8

MOWSE Score: 9.0085540e+005

Likelihood: 6.84e+003

Coverage: 49.20 %

Matching peptides:

MW Delta Start End Sequence

816.4018 -121.38 124 130 (K)SVSFS YK(G)

816.4527 -58.95 155 161 (K)IMIGV ER(S)

933.4668 -106.00 61 68 (K)LGNNV DFR(I)

1051.6390 -108.98 173 181 (R)IESLP IKPR(G)

1570.7528 -54.97 99 111 (K)HWSIW QIQDS SGK(E)

2148.0739 -18.35 21 39 (R)IGQDD LPGFD LISQF QIDK(A)

2183.0687 -25.77 73 90 (R)HLYPN GLPEE YSFLT TFR(M)

832.4476 -81.84 155 161 (K)IMIGV ER(S)

+ Methionine Sulfoxide

1282.5976 -93.79 162 172 (R)SSATL FVDCN R(I)

+ Cysteine acrylamide

21

Q95L50

Type IX collagen alpha 1 chain**Molecular weight: 20907**

Matches: 8

MOWSE Score: 9.0085540e+005

Likelihood: 6.26e+003

Coverage: 49.20 %

Matching peptides:

MW Delta Start End Sequence

816.4018 -133.87 124 130 (K)SVSFS YK(G)

816.4527 -71.44 155 161 (K)IMIGV ER(S)

933.4668 -113.93 61 68 (K)LGNNV DFR(I)

1051.6390 -115.35 173 181 (R)IESLP IKPR(G)

1570.7528 -60.83 99 111 (K)HWSIW QIQDS SGK(E)

2148.0739 -9.04 21 39 (R)IGQDD LPGFD LISQF QIDK(A)

2183.0687 -23.66 73 90 (R)HLYPN GLPEE YSFLT TFR(M)

832.4476 -68.62 155 161 (K)IMIGV ER(S)

+ Methionine Sulfoxide

1282.5976 -93.25 162 172 (R)SSATL FVDCN R(I)

+ Cysteine acrylamide

- The most abundant polypeptide fragments present in those isolated from CaP by the ion exchange method were derived from the NC4 domain of the type IX collagen α 1 chain [Molecular weight: 27,139Da, (Vasios G, Nishimura I, Konomi H, van der Rest M, Cartilage Type IX collagen-proteoglycan contains a large amino-terminal globular domain encoded by multiple exons. J Biol Chem **263**: 2324-2329,1988)]. This is evident by combining the sequences obtained from the trypsin generated products shown in Table 7 for: Polypeptide 10, Polypeptide 13, Polypeptide 14, Polypeptide 15, Polypeptide 16, Polypeptide 17, Polypeptide 18, Polypeptide 20 and Polypeptide 21 and super-imposing them on part of the bovine NC4 domain of the α 1(IX) chain as shown in Table 8 below. This conclusion is also supported by comparison of the observed peptide sequences with the published NC4 domain of the α 1(IX) chain from chick sterna (Vasios G, Nishimura I, Konomi H, van der Rest M, Cartilage Type IX collagen-proteoglycan contains a large amino-terminal globular domain encoded by multiple

exons. J Biol Chem **263**: 2324-2329,1988) and shown in Table 2. Furthermore the estimated molecular weights and isoelectric points of Polypeptide 13, Polypeptide 14, Polypeptide 15, Polypeptide 16, Polypeptide 17, and Polypeptide 18 shown in Table 1 are consistent with their origin as the NC4 domain of the $\alpha 1(\text{IX})$ chain which has a molecular weight of about 27,00Da and isoelectric point of 9.7.

Table 8 show the partial amino acid sequence of the bovine NC4 domain of type IX collagen alpha 1 chain sequence obtained from the ExPASy TrEMBL database on which the peptide sequences obtained from the MALD-MS peptide mass fingerprinting of gel spot 13 (Figure 4) has been superimposed as bolded type where they are identical.

Table 8: (SEQ ID NO. 20)

10	20	30	40	50	60
PRFPVNSNSN	GENELCPKVR	IGODDLPGFD	LISQFQIDKA	ASRRAIQRVV	GSTALQVAYK
70	80	90	100	110	120
LGNNVDFRIP	TRHLYPNGLP	E EYSFLTTFR	MTGSTLEKHW	SIWQIODSSG	KEQVGVKING
130	140	150	160	170	180
QTK SVSFSYK	GLDGLQTAA	FSNLPSLFDS	QWHKIMIGVE	RSSATLFVDC	NRIESLPKIP
RGQIDVD					

While the 4 non-collagenous domains (NC1, 2, 3 and 4, Figure 1) along the type IX collagen $\alpha 1$ chain are known to be the most susceptible regions to proteolytic cleavage by a wide range of proteinases, the NC4 domain is the most venerable of these regions because of its physical extension beyond the COL3 domain and the rest of the alpha chain which together with the other 2 alpha chains lies on the surface of the type II collagen fibril. The results obtained previously also indicate that the endogenous cathepsin family of proteinases were largely responsible for the release of matrix peptides fragments from cartilage under the conditions described herein. Significantly, that the NC4 domain of type IX collagen alpha 1 chain is rich in Arginine residues which constitutes part of the preferred cleavage sites for the cathepsins (Maciewicz RA, Etherington DJ. A comparison of four cathepsins (B,L,N and S) with collagenolytic activity from rabbit spleen, Biochem. J, **256**: 433-4440, 1988).

The finding of a fragment (Polypeptide 2) of bovine cartilage oligomeric matrix protein (COMP) (peptides 2 and 3) in the polypeptides from the ion-exchange supernatants is also supportive of the proteolytic cleavage of the NC4 domain of type IX collagen alpha 1 chain. COMP through its C-terminal domain is known to interact with the non-collagenous domains (NC1-4) of the type IX collagen alpha 1 chain and could be enzymatically processed when the NC4 domain is cleaved from the rest of the type IX collagen alpha-1 chain since these two proteins are strongly associated and play key structural roles in the assembly of the extracellular matrix of cartilage. As already mentioned, the type IX collagen is located on the surface of the type II collagen fibrils where it serves as cross linking units between fibrils and itself. It was therefore surprising to find that none of the polypeptides isolated contain any peptides originating from the type II collagen molecule suggesting that the autolytic process is selective for the NC4 domain of the type IX collagen molecule.

Fragments of Bovine Serum Albumin (Molecular weight: 69294) (Polypeptide 7, Polypeptide 8, Polypeptide 9, Polypeptide 11, Polypeptide 12) were also found in the polypeptide fraction of CaP (Table 7). The presence of fragments of this protein was not unexpected in view of the large reservoir available in the blood of tissues adjacent to the tracheal cartilage.

Neutrophil cytosol factor 1 (Molecular weight: 45346) (Polypeptide 1 and Polypeptide 9), Odorant-binding protein (Molecular weight: 18503) (Polypeptide 19) have not previously been reported to be present in cartilage and their functions, if any, are therefore unknown. Odorant-binding protein has however, been identified in bovine nasal mucosa endothelium which is physically close to the trachea. It is possible that this protein is sequestered to the tracheal cartilage and is not in fact a chondrocyte biosynthetic product. Since bovine odorant protein is not a cartilage derived antigen it would not be expected to be effective in the collagen induced arthritis model used to identify ant-arthritis activity in the present application.

Table 9(a) shows an amino acid sequence of cartilage oligomeric matrix protein (fragment) - bovine and 9(b) shows an amino acid sequence for odorant binding protein - bovine obtained from the ExPASy TrEMBL database on which the peptide sequences obtained from the peptide mass fingerprinting of gel spots 2 and 19 respectively have been superimposed as bolded type where they are identical.

Table 9a: (SEQ ID NO. 12)

Cartilage oligomeric matrix protein [Fragment] – bovine

10	20	30	40	50	60			
DGVLNEK	<u>DNC PLVR</u>	NPDPQRN	TDGDK	<u>WGDAC</u>	<u>DNCR</u>	SQKNDD	QKDTDKDGR	<u>G DACDDDDIDG</u>
70	80	90	100	110	120			
<u>RIRNPVDNCP</u>	<u>KVPNSDQKDT</u>	DGDGVGDACD	NCPQKSNADQ	RDVDHDFVGD	ACDSQDQDG			
130	140	150	160	170	180			
DGHQDSKDNC	PTVPNSAQD	SDHDGQGQDAC	DDDDNDNGVF	DSRDNCR	<u>LVP NPGQEDMDRD</u>			
190	200	210	220	230	240			
GVGDACQDGF	DADKVVDKID	VCPENAEVTL	TDFRAFQTVV	LDPEGDAQID	PNWVVLNQGM			
250	260	270	280	290	300			
EIVQTMNSDP	GLCVGYTAFN	GVDFEGPPFHV	NTATDDDYAG	FIFGYHHSSS	FYVVMWKQME			
310	320	330	340	350	360			
QTYWQANPFR	AVAEPGIQLK	AVKSSTGPGE	QLRNALWHTG	DTASQVRLIW	KDPRNVGWKD			
370	380	390	400	410	420			
KTSYRWFLQH	RPQVGYYRVR	FYEGPELVAD	SNVILDTTMR	GGRLGVFCFS	QENIIWANLR			
430								
YRCNDTIPED	YEAORLLQA							

Table 9b: (SEQ ID NO. 13)

5 Odorant-binding protein - bovine

10	20	30	40	50	60	
AQEEEEQNQL	SELSGPWR	<u>TV YIGSTNPEKI</u>	<u>QENGPFRTYF</u>	<u>RELVFDEDEK</u>	<u>TVDFYFSVKR</u>	
70	80	90	100	110	120	
DGKWKNVHVK	ATK	<u>QDDGTYV</u>	<u>ADYEQNVFK</u>	IVSLSR	<u>THLV AHNINVDK</u>	HG QTTELTFLV
130	140	150				
KLNVEDEDLE	KFWKLTEDEK	IDKK	<u>NVVNFI</u>	<u>ENEDHPHPE</u>		

In this respect it was significant that the polypeptides retained by using a TFF membrane with a protein cut-off of >30,000Da were in-active in the rat CIA model (data not shown). On the other hand those polypeptides obtained in the dialysate with

molecular weights <30,000Da (INR-126 and INR-195) were active both active as tolerants and prophylactic anti-arthritis agents (Figures 6-7 and Tables 5-6). Furthermore, since the anti-arthritis activity of INR-126 (MW range 1000Da-30,000Da) appeared to be only slightly more active as a toleragen in the CIA model than INR-195 (MW range 10,000Da- 30,000Da) it may be deduced that the majority of the anti-arthritis activity resides in polypeptides within the MW range of 10,000-30,000Da which corresponds to peptides 11, 12, 13, 14, 15, 16, 17, 18, 20, 21 (Table 1).

The NC4 domain of the α 1(I) chain or fragments derived from it have not previously been reported to exhibit anti-arthritis activity.